

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Effect of home-based high-intensity interval training and behavioral modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: the habit-B study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030911
Article Type:	Protocol
Date Submitted by the Author:	08-Apr-2019
Complete List of Authors:	<p>Tsuji, Katsunori; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Ochi, Eisuke; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences; Hosei University, Faculty of Bioscience and Applied Chemistry Okubo, Ryo; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Shimizu, Yoichi; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Kuchiba, Aya; National Cancer Center Japan, Division of Biostatistical Research, Center for Public Health Sciences; National Cancer Center Japan, Biostatistics Division, Center for Research Administration and Support Shimazu, Taichi; National Cancer Center Japan, Division of Prevention, Center for Public Health Sciences Kinoshita, Takayuki; National Cancer Center Hospital, Department of Breast Surgery Sakurai, Naomi; Cancer Solutions Matsuoka, Yutaka; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences</p>
Keywords:	Breast tumours < ONCOLOGY, SPORTS MEDICINE, PREVENTIVE MEDICINE, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts

BMJ Open Study protocols

Effect of home-based high-intensity interval training and behavioral modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: the habit-B study protocol for a randomized controlled trial

Katsunori Tsuji^{1*}, Eisuke Ochi^{1, 2*}, Ryo Okubo¹, Yoichi Shimizu¹, Aya Kuchiba^{3,4}, Taichi Shimazu⁵, Takayuki Kinoshita⁶, Naomi Sakurai⁷, Yutaka J. Matsuoka¹

1. Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
2. Faculty of Bioscience and Applied Chemistry, Hosei University, Tokyo, Japan
3. Division of Biostatistical Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
4. Biostatistics Division, Center for Research Administration and Support, National Cancer Center Japan, Tokyo, Japan
5. Division of Prevention, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
6. Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan
7. Cancer Solutions, Tokyo, Japan

* These two authors contributed equally to this work

Corresponding author

Yutaka J. Matsuoka, MD, PhD

Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan

E-mail address: yumatsuo@ncc.go.jp, Phone: +81-3-3547-5201 ext. 3382

ABSTRACT

Introduction

Maintaining high levels of physical activity not only helps to maintain and improve physical health and quality of life, but also plays a role in reducing short- and long-term adverse effects due to cancer treatments. Moreover, a greater degree of cardiorespiratory fitness is associated with reduced risk of all-cause mortality. However, there are no home-based programs for improving cardiorespiratory fitness using body weight exercises for breast cancer survivors. This study will assess the efficacy of the newly developed habit-B program on maximum oxygen uptake compared with treatment as usual. The effects of this program on exercise habits, level of physical activity, physical fitness, and subjective indices will also be investigated.

Methods and analysis

This is a 12-week, parallel-group, single blind, randomized controlled trial. Allocation will be managed by a central server using a computer-generated random allocation sequence provided by an independent data center. Participants will be assigned to the Habit-B Program (high-intensity interval training [HIIT] exercise, exercise counseling + guidance, home-based exercise support using information and communication technology [ICT], and a wearable device) or treatment as usual with a wearable device. Subjects will be sedentary women aged 20 to 59 years who have received breast surgery in the past 2 to 13 months after diagnosis of invasive breast cancer (Stage I-IIa) and have never received neo-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

adjuvant or adjuvant chemo-therapy except for hormone therapy. The primary endpoint is the amount of change in peak oxygen uptake (VO_{2peak} ; mL/kg/min) between the groups after 12 weeks of intervention.

Ethics and dissemination

The study protocol was approved by the Institutional Review Board of the National Cancer Center Japan on 28 February 2019 (ID: 2018-274).

Trial status Study enrolment, intervention, and data collection are ongoing. The estimated end date for this study is on March 31, 2021.

Trial registration number UMIN000036400; Pre-results.

Strengths and limitations of this study

1. If the findings of this trial suggest that the intervention is effective, it is expected to lead to establishing an effective exercise program for breast cancer survivors in Asia; VO_{2peak} of breast cancer survivors will be improved and exercise habits will be formed.
2. By achieving the trial objectives, it will become possible to suggest a home exercise program.
3. Data on clinical problems and participants' opinions obtained in this study can subsequently be utilized in the dissemination and implementation of future programs.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4. Even if implementation, effectiveness, or usefulness are not demonstrated, analyzing the cause of this should contribute to planning a new exercise program.
 5. Collaborative work with professionals in the field of clinical oncology, exercise science, mental health, rehabilitation, public health, nursing, and cancer survivors constitutes a new model for cancer survivorship care.

INTRODUCTION

Breast cancer, which is one of the most common cancers affecting women, newly affects over 86,000 women each year¹. Advances in early detection and treatment have improved survival rates, with the current 10-year survival rate at over 90%¹. It is recommended that cancer survivors acquire and maintain healthy behaviors to extend survival, such as staying reasonably fit through appropriate physical exercise and having a healthy diet². High levels of physical activity not only help to maintain and improve physical health and quality of life (QOL), but also play a role in reducing short- and long-term side effects of cancer treatment³. The American Cancer Society guidelines recommend a minimum of 150 min moderate physical activity or 75 min intensive physical activity per week, in addition to usual physical activity in daily life⁴, and the Japan Breast Cancer Society's Clinical Guidelines for Breast Cancer strongly recommend maintaining a high level of physical activity^{5 6}. Exercise is effective in treating breast cancer because it significantly improves physical function, mental health, and physiological markers before, during, and after cancer treatment^{5 6}. A US study previously reported that following breast cancer diagnosis, less than half of patients maintained a level of physical activity at or above the recommended standards⁷. We assume that the proportion of individuals with a habit of exercising is low among breast cancer survivors as well and that very few maintain a high level of physical activity in Japan.

1
2
3
4
5
6 Previous studies of physical activity and exercise intervention among breast
7
8 cancer survivors have mainly focused on weight gain^{8 9}, impairment of endothelial
9
10 function¹⁰, lower bone density in post-menopausal women¹¹, and lower physical
11
12 fitness^{12 13}. The ENERGY Trial, an early and representative study conducted in the
13
14 US, demonstrated the effectiveness of a home exercise program and nutritional
15
16 advice to promote weight loss among breast cancer survivors⁸. However, because
17
18 the proportion of overweight adults in Japan is lower than that in the US¹⁴, it is not
19
20 appropriate to adopt the US-developed program in Japan. It would appear suitable
21
22 though to develop intervention around measurements of VO_{2peak} , the globally
23
24 important health indicator of cardiorespiratory fitness^{15 16}.

25
26
27
28
29
30
31 VO_{2peak} decreases with age, and a meta-analysis has suggested that women
32
33 who are sedentary have a decrease of 3.2 mL/kg/min over 10 years¹⁷. A cohort
34
35 study suggested that the all-cause mortality rate decreased by 17% for each 1
36
37 metabolic equivalent (MET) increase (3.5 mL/kg/min) in VO_{2peak} for women¹⁸.
38
39 Also, individuals who met the standards for physical activity had a relative risk of
40
41 0.76 compared with those engaging in no physical activity, and individuals with a
42
43 moderate VO_{2peak} had a relative risk of 0.56 compared with those with a low
44
45 VO_{2peak} . Thus, maintaining a high VO_{2peak} has great benefits in terms of all-cause
46
47 mortality rate¹⁹. A systematic review demonstrated that the median VO_{2peak} of
48
49 breast cancer survivors not receiving chemotherapy was lower than that of
50
51 healthy sedentary women (25.3 mL/kg/min vs. 29.7 mL/kg/min)¹³. In a 16-year
52
53 follow-up study of breast cancer survivors¹³, hazard ratios were 0.67 for the
54
55
56
57
58
59
60

1
2
3
4
5
6 moderate VO_{2peak} group (8.5 METs) and 0.45 for the high group (11.1 METs)
7
8 compared with the low VO_{2peak} group (6.7 METs). In this report, the mortality rate
9
10 was reduced by maintaining a VO_{2peak} of 8 METs or above¹³. Against this
11
12 background, it is necessary to develop an exercise program that will increase
13
14
15
16 VO_{2peak} in breast cancer survivors.

17
18
19 When considering how to increase VO_{2peak} , research has advanced in recent
20
21 years with the use of HIIT for athletes and sedentary populations²⁰⁻²². HIIT allows
22
23 subjects to exercise at vigorous intensity within 10 min, resulting in improved
24
25 cardiorespiratory fitness^{16 23}. A recent systematic review showed, based on the
26
27 findings of 12 studies of HITT conducted in supervised experimental settings, that
28
29 HITT appeared to be more beneficial than treatment as usual for improving
30
31 physical fitness and health-related outcomes in cancer survivors during any stage
32
33 of treatment and aftercare²³. To our knowledge, only one study has evaluated
34
35 changes in cardiorespiratory fitness following a home-based HITT program, which
36
37 involved healthy young women²⁴. Given that no home-based HIIT programs with
38
39 body weight exercises have been reported for breast cancer survivors to date, it is
40
41 necessary to develop such programs and examine their efficacy and feasibility.
42
43
44
45
46
47

48
49 Recent emerging technologies such as apps and wearable devices are
50
51 promising tools for the monitoring of cancer patients' daily activity levels and for
52
53 facilitating coaching, self-monitoring, feedback, and encouragement to
54
55 exercise^{25,26}. Apps²⁷ and wearable devices²⁸ are being used for both subjective and
56
57 objective measures in the field of clinical oncology. However, further investigations
58
59
60

1
2
3
4
5
6 are needed of their potential utility in objective evaluations of physical activity as
7
8 well as in lifestyle modification and maintenance and enhancement of QOL in real-
9
10 world settings.
11
12

13 The aim of this study is to investigate the effect of the newly developed
14 habit-B program, comprising home-based high-intensity interval training and
15 behavioral modification using information and communication technology on
16 cardiorespiratory fitness and exercise habits for sedentary breast cancer
17 survivors. We will investigate whether the habit-B program improves VO_{2peak}
18 compared with a control group as well as investigate the safety and feasibility of
19 program. The secondary objectives are to investigate the effect of this program on
20 exercise habits, physical activity level, physical function, and subjective measures.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

Trial design (Figure 1)

In this study 12-week, parallel-group, single blind, randomized controlled trial, participants will be randomly assigned to intervention either with the habit-B program (HIIT exercise, exercise counseling + guidance, home-based exercise support using ICT, and a wearable device) or treatment as usual with a wearable device. An independent data center will provide computer-generated random allocation. The allocation sequences will be maintained centrally and the results of the assignment will be automatically displayed on each participant's app.

Participants

The eligibility criteria for participants are as follows: (1) female, aged between 20 and 59 years at diagnosis (stages I-IIa); (2) diagnosed with invasive breast cancer within 2 to 13 months after surgery; (3) not requiring cancer chemotherapy aside from hormone therapy; (4) currently engages in not more than moderate intensity exercise for 30 min on 2 separate days per week (total of 60 min); (5) ability to complete an electronic patient reported outcome (e-PRO) questionnaire via a smartphone; (6) consent to trial participation obtained in writing from the patient themselves; and (7) ability to read, write, and understand Japanese. The exclusion criteria are as follows: (1) judged to have severely reduced cognitive function by a primary physician; (2) exercise judged to be risky by a primary physician; (3) history of smoking within the previous 12 months; (4) body

1
2
3
4
5
6 mass index of 30 or above; (5) abnormal electrocardiogram in preoperative
7
8 testing, resting heart rate (HR) below 60 beats/min or above 100 beats/min, or
9
10 stage III hypertension or above (diastolic blood pressure over 110 mmHg or
11
12 systolic blood pressure over 180 mmHg); and (6) judged unfit for the trial by a
13
14 primary physician for other reasons.
15
16
17
18
19
20

21 **Interventions**

22
23 This will be a randomized, single-blind study. Participants will be
24
25 enrolled and assigned using an electronic data capture system with an app. The
26
27 protocol intervention will be started within 21 days of enrollment. If for some
28
29 reason the start is delayed beyond 21 days, the reason will be entered into the
30
31 electronic Case Report Form (eCRF). If it is determined that the intervention
32
33 cannot be started, the details will be noted in the eCRF as “protocol intervention
34
35 stopped.”
36
37
38
39
40
41
42
43

44 The habit-B program group

45
46 The habit-B program comprises home-based exercise support utilizing 6
47
48 weeks of exercise counseling/exercise guidance and 12 weeks of ICT intervention
49
50 (e-mail, app, wearable device; shown in Figure 2). Participants will be encouraged
51
52 to complete the following program HIIT using specific body weight exercises for a
53
54 10-min training session 3 times a week for 12 weeks (total of 36 sessions during the
55
56 trial period; Figure 3): (1) one 10-min session of exercises focused on the lower
57
58
59
60

1
2
3
4
5
6 limbs; (2) a total of 10 min exercises, comprising a 3-min warm-up, 4-min training
7
8 (8 sets of 20 s exercise + 10 s rest), and a 3-min cool-down; (3) these training
9
10 exercises are designed to increase in intensity each week; and (4) the details of these
11
12 exercises are divided into three stages according to cardiorespiratory fitness
13
14 (VO_{2peak}) at Week 0 and the contents of training are designed to increase physical
15
16 strength incrementally in accordance with the individual's level of strength. In
17
18 addition, we will continue to follow up on the between-group differences in e-PRO
19
20 data of change from baseline to 24 and 36 weeks post-intervention.
21
22
23
24
25

26 The social cognitive theory proposed by Bandura et al. may be helpful to
27
28 apply when considering interventions for behavioral change²⁹, chiefly in that it
29
30 affords a framework for understanding the underlying reasons for making and
31
32 maintaining health behaviors³⁰. Its key concepts involve (1) understanding of health
33
34 risks and benefits, (2) perceived self-efficacy of being able to control one's own
35
36 health habits, (3) projected costs and benefits or expected outcomes, (4) specified
37
38 health goals with short- and long-term intentions to engage in the behavior, (5)
39
40 perceived facilitators and social support, and (6) barriers to instituting change^{29 30}.
41
42 In the present study, we developed the exercise program applying the first 5
43
44 concepts.
45
46
47
48
49

50
51 We will also provide the participant a brochure as a reminder to exercise and
52
53 will check the type of physical activity they engage in in daily life (Figure 4). When
54
55 developing the habit-B program, we collaborated closely with exercise scientists,
56
57 oncologists, physical therapists, nurses, mental health practitioners, and breast
58
59
60

1
2
3
4
5
6 cancer survivors.
7
8
9

10 Control group

11
12
13 The control group will be provided a wearable device and setup support
14
15
16 at the start of intervention. Self-monitoring using the wearable device will be
17
18 recommended during the trial period. While there are no reports of increasing
19
20 VO_{2peak} with the use of a wearable device alone, other reports have ruled out their
21
22 efficacy with regard to effects on exercise habits³¹. In this study, the wearable
23
24 devices are used only to monitor physical activity in the control group.
25
26
27
28
29
30

31 PROCEDURE

32 Data collection, management, monitoring, and auditing

33
34 We will collect all data except qualitative interview data, blood samples,
35
36 fecal samples, and medical economic costs through the e-PRO system. Those who
37
38 provide consent will be enrolled in the app-based e-PRO system on their
39
40 smartphone. If the entered data is insufficient, enrollment will not be accepted
41
42 until all fields are completed at baseline. The electronic data capture system will be
43
44 used for data management and central monitoring. Because this exercise program
45
46 will not be invasive, there is no need to establish a data monitoring committee or
47
48 to complete auditing in this study.
49
50
51
52
53
54
55
56
57
58
59
60

Random assignment and assignment adjustment factors

1
2
3
4
5
6 After enrollment and the additional input of the VO_{2peak} value, patients
7
8 will be randomly assigned. In the process of random assignment, VO_{2peak} (obtained
9
10 from the baseline measurement performed after obtaining informed consent) and
11
12 age will be used as assignment adjustment factors, and automatic assignment will
13
14 be performed using the data center's assignment feature. Only the measurer will
15
16 be blinded in this study, because interventions differ for the intervention group
17
18 and control group.
19
20
21
22
23
24
25

26 **Dataset availability**

27
28 The data sharing policy in this study is defined with reference to the
29
30 example proposed by the International Committee of Medical Journal Editors
31
32 (ICMJE): Individual participant data will be made publicly available for a 5-year
33
34 period through the University Hospital Medical Information Network – Individual
35
36 Case Data Repository (UMIN-ICDR) (<https://www.umin.ac.jp/icdr/index-j.html>).
37
38
39
40
41
42
43

44 **Concomitant treatments**

45
46 There are no regulated concomitant therapies or supportive therapies in
47
48 this study.
49
50
51
52

53 **Stopping rules for participants**

54
55 Situations in which the intervention protocol is terminated for any of the
56
57 following reasons will be defined as stopping of the protocol intervention: (1)
58
59
60

1
2
3
4
5
6 dropping out due to withdrawal of consent or inability to measure the primary
7
8 endpoint (VO_{2peak}); (2) if a primary physician deems it necessary to stop the
9
10 protocol intervention for a participant due to adverse events such as stress; (3)
11
12 death of the patient during the protocol intervention period; (4) sudden worsening
13
14 of the participant's condition after enrollment or discovery of a protocol violation
15
16 or ineligibility. A researcher will report the reason for stopping the protocol
17
18 intervention to the data center. In this event, as long as consent is not withdrawn,
19
20 follow-up including the questionnaire survey will be continued.
21
22
23
24
25
26
27
28

29 **Stopping of the assessment**

30
31 Situations in which the participant declines assessment will effectively
32
33 stop the assessment. A researcher will confirm the possibility of implementing the
34
35 remaining parts of the intervention and follow-up with the participant. Stopping of
36
37 the assessment will be recorded along with the details of the reason for stopping.
38
39 As a rule, the remaining aspect of follow-up will be implemented as stipulated per
40
41 protocol.
42
43
44
45
46
47
48

49 **Assessment measures**

50
51 Table 1 shows the outcome measurement schedule.
52
53
54
55

56 Primary outcome measure: Cardiorespiratory fitness (VO_{2peak})
57
58
59
60

1
2
3
4
5
6 VO_{2peak} is the maximum oxygen uptake observed during exercise
7
8 tolerance testing and is used as an indicator of cardiorespiratory fitness^{32 33}. For
9
10 each participant, VO_{2peak} will be measured using the incremental multistage load
11
12 method with a bicycle ergometer (Ergomedic 828E, Monark, Stockholm, Sweden)
13
14 at 60 revolutions per min (rpm). The test will begin at 0.5 kp and increase by 0.25
15
16 kp per min until exhaustion. When the participant's pedal rotation speed drops
17
18 below 55 rpm 3 times, the test will be deemed concluded. Respiratory gases will be
19
20 analyzed using an automatic gas analyzer (Air Monitor AE-310S, Minato Medical
21
22 Science Co., Ltd., Osaka, Japan). Rated perceived exertion and HR will be recorded
23
24 after 45 s in each stage. The maximum value of VO_2 observed during exercise will
25
26 be used as the VO_{2peak} .
27
28
29
30
31
32
33
34
35

36 Secondary outcome measures

37 *Physical function*

38
39 An alternative indicator of VO_{2peak} , the 6-min walk test (m), will be
40
41 performed³⁴. Walking speed (m/s), a diagnostic criterion for sarcopenia, will also
42
43 be measured. A 5-m section in the middle of an 11-m line will be measured to
44
45 calculate walking speed³⁵. One-repetition maximum for leg press, which reflects
46
47 muscle strength in the lower body, will be assessed using a leg press machine^{36 37}.
48
49 After a thorough warm-up, measurements will be performed by incrementally
50
51 increasing the load until a weight, which can be lifted only once, is reached. Load
52
53 will be increased by two levels at a time. Grip strength will also be measured^{37 38}.
54
55
56
57
58
59
60

1
2
3
4
5
6 The chair stand test, which reflects combined leg strength for the lower limbs as a
7 whole, will be performed^{37 39}. Participants will sit and stand from a chair for 10 s
8 and the number of chair stands will be measured. The timed up and go test, which
9 is used in clinical settings as an assessment of functionality as well as muscular
10 strength, will also be performed³⁷. The functional reach test, which as a method of
11 assessing dynamic balance is considered an indicator of expected fall risk, will also
12 be performed⁴⁰. While keeping the hand at the same height, the participant will
13 extend their arm forward as far as possible, without moving the feet, to make a
14 mark at the farthest point they can reach. Lifting the heels and standing on tiptoe is
15 allowed. The two-step test will also be performed⁴¹. This test comprehensively
16 assesses ability to walk, including leg strength, balance, and flexibility. Based on
17 bioelectrical impedance analysis, a body composition meter (MC-780A-N, TANITA,
18 Japan) will be used to send a weak electrical current through the body via
19 electrodes.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Physical activity level*

45
46 The Global Physical Activity Questionnaire (GPAQ) was developed in
47 2002 as an internationally standardized questionnaire for surveying physical
48 activity level. The GPAQ is widely used in policy development by the World Health
49 Organization⁴²⁻⁴⁴. The face validity of the Japanese version has been confirmed⁴⁵.
50
51 In addition, as an objective measure of physical activity during the research period,
52 resting HR, steps, distance, calorie expenditure, and the duration of each sleep
53
54
55
56
57
58
59
60

1
2
3
4
5
6 stage as well as wake up time will be measured using an activity monitor and
7
8 logged for 24-h periods (Fitbit versa, Fitbit Inc., San Francisco, CA). Maximum HR
9
10 during exercise will also be measured to confirm whether the intensity of the
11
12 exercise being implemented is appropriate. The accurately measured group will be
13
14 defined as the group who wears the Fitbit versa at least 60% of the time during the
15
16 12-week intervention period.
17
18
19
20
21
22

23 *Subjective measures*

24
25
26 Fear of cancer recurrence (FCR) will be assessed by the overall fear index
27
28 score on the Concerns About Recurrence Scale^{46 47}. This instrument comprises 4
29
30 items scored on a 6-point Likert scale (range, 1–6), with a higher score indicating
31
32 worse FCR. Depression will be assessed using the Patient Health Questionnaire-9
33
34 ⁴⁸. Fatigue will be assessed by the Cancer Fatigue Scale. Sleep will be assessed by
35
36 the Athens Insomnia Scale^{49 50}. Health-related QOL will be assessed using the
37
38 EuroQol 5 Dimensions questionnaire^{51 52}.
39
40
41
42
43
44
45

46 *Biological assessments*

47
48 To assess changes in gut microbiota, intestinal metabolites, and intestinal
49
50 immunity, a 1-g fecal sample will be obtained at baseline and at 12 weeks. Blood
51
52 concentrations of polyunsaturated fatty acids will be assessed from capillary dried
53
54 blood spot samples (approximately 80 μ L) at baseline⁵³.
55
56
57
58
59
60

Medical economic costs

For cost-benefit analysis, the number of staff, working hours, labor costs, equipment costs, office expenses, number of unexpected medical consultations, direct medical costs, and costs of other medical services used will be obtained.

Harms

The intervention in this research will potentially place stress on participants physically and in terms of their time, because it will take approximately 1 h and 30 min. There will also be temporary exhaustion, although individual differences will be considered in exercise implementation. There are no financial risks associated with participation in the study.

Compensation

If participants develop unexpected health issues due to study participation during or after completion of the study, treatment will be provided appropriately in the same way as standard medical care. Medical expenses at that time will be handled within the medical insurance to which the participant is enrolled. No financial compensation, except for providing the wearable device, will be given in this study.

DATA ANALYSIS

1
2
3
4
5
6 The primary endpoint, VO_{2peak} , will be calculated as follows.
7

8
9 Measurements will be taken at the start of the intervention (0 week) and at the
10
11 conclusion of the intervention (12 weeks). The analysis set for primary analyses
12
13 will consist of all randomized subjects. After completing primary endpoint data
14
15 locking, analyses centering on the primary endpoint will be performed. The
16
17 objective of primary analysis in this study is to investigate whether the habit-B
18
19 program group (trial treatment group) surpasses the group receiving treatment as
20
21 usual (control) in VO_{2peak} the primary endpoint. One-sided tests will be used,
22
23 because, if the trial intervention group is inferior to the control group, it is not
24
25 important in this trial whether that difference is statistically significant. The trial
26
27 will adopt a one-sided significance level of 2.5%. A between-groups comparison
28
29 will be performed using an independent two-sample t-test to determine the
30
31 significance of amount of change in VO_{2peak} (mL/kg/min) from 0 week to 12 weeks
32
33 (after intervention completion) between the trial intervention and the control
34
35 groups. Secondary endpoint analyses will be performed with the goal of
36
37 supplementing the primary analyses. Once all data has been locked following
38
39 conclusion of the primary analysis period and follow-up, final analyses will be
40
41 performed.
42
43
44
45
46
47
48
49
50
51

52 53 **Sample size estimation**

54
55
56 The main hypothesis of this study is that the intervention group will
57
58 significantly surpass the control group in terms of the amount of change in VO_{2peak}
59
60

1
2
3
4
5
6 from 0 week to 12 weeks. Regarding the clinical significance of the results of an
7
8 exercise program, it is common to use an increase of 10% in VO_{2peak} to evaluate the
9
10 effects of an exercise program⁵⁴. As such, an increase of 10% from VO_{2peak} at the
11
12 start of exercise has been established for this trial. According to a previous study of
13
14 intervention similar to that in the present study⁵⁵, the standard deviation for the
15
16 VO_{2peak} of the intervention group was 2.6 mL/kg/min. Based on the above
17
18 hypothesis, by estimating the number of subjects required for a one-sided 2.5%
19
20 and a power of 80% in the analysis, 28 individuals per group are necessary for a
21
22 total of 56 in both groups (SAS 9.4 software; SAS Institute Inc., Cary, NC). With the
23
24 estimation that 4 participants will drop out, enrollment of 60 patients is planned.
25
26
27
28
29
30
31
32

33 **Study period**

34
35
36 The study period of this trial will be from April 2019 to March 2021; the
37
38 participant entry period will be from April 2019 to March 2020. Study enrolment,
39
40 intervention, and data collection are ongoing.
41
42
43
44
45

46 **PATIENT AND PUBLIC INVOLVEMENT STATEMENT**

47
48 This study protocol was designed with the involvement of a breast cancer
49
50 survivor who participated in this study as a researcher and coauthor. She
51
52 discussed issues with other survivors in instances where survivors' preferences
53
54 and opinions should be considered. In the process of creating the habit-B program,
55
56
57
58
59
60

1
2
3
4
5
6 we conducted a preliminary confirmation of the feasibility and safety of this
7
8 program in 5 breast cancer survivors.
9

10 11 12 13 **ETHICAL CONSIDERATIONS AND DISSEMINATION** 14

15
16 The protocol was approved by the Institutional Review Board of the
17
18 National Cancer Center Research Ethical Review Committee on 28 February 2019
19
20 (ID: 2018-274). The results obtained will be submitted for publication in a peer-
21
22 reviewed international journal, and the main relevant findings will be presented at
23
24 conferences.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

An excellent review by Shapiro et al. affirms the positive role that high levels of physical activity play in improving not only health-related QOL and symptom management (e.g., chronic pain, fatigue, insomnia, sexual dysfunction, metabolic syndrome, bone loss, cognitive dysfunction, and depression), but also return to work in cancer survivors³. In addition, increased cardiorespiratory fitness may decrease all-cause mortality among cancer survivors^{12,56}. However, there are currently no effective home-based exercise programs available for improving cardiorespiratory fitness for breast cancer survivors. No studies have precisely investigated cardiorespiratory fitness⁵⁷, although a small pilot study did estimate VO_2 based on subjective exercise intensity among Japanese breast cancer survivors. Accordingly, the present study seeks to confirm whether our originally developed home-based exercise program (habit-B program) improves VO_{2peak} compared with treatment as usual in sedentary breast cancer survivors in Japan. With the assumption that the program will be widely implemented if successful, it was designed to be (1) home based, (2) quick to implement (only 10 min in total), (3) use only body weight exercises involving the lower limbs, and (4) utilize a wearable device for which personalized ICT support is available. We believe that no similar studies have been implemented.

If it is found that the habit-B program is effective in increasing VO_{2peak} , we will then proceed to the next trial, aiming for its widespread implementation in society. Specifically, the aims of the next study will be (1) to investigate whether

1
2
3
4
5
6 intervention using the program developed in this research but presented in a
7
8 simpler format is effective in establishing exercise habits and (2) to assess whether
9
10 the program can be implemented in societies in Eastern Asia, including in both
11
12 urban and rural Japan and other East Asian countries.
13
14

15
16 We strongly believe that a successful support team comprising specialists in
17
18 the field of exercise science, medicine, rehabilitation, nursing, and patient
19
20 advocacy, as involved in this study, will provide a new horizon in cancer
21
22 survivorship care.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We sincerely thank Dr. Hiroji Iwata, Dr. Hirokazu Arai, Ms. Noriko Watanabe, Dr. Noriaki Tatematsu, Dr. Hikaru Ihira, Mr. Tomoyasu Chigahara, Dr. Taro Ueno, Dr. Shinji Fukuda, and Dr. Eiko Saito for their generous support for the study. We also thank Ms. Ayako Sato for her role as an exercise model.

Contributors KT, EO, RO, YS, TK, and YM conceived the study and drafted the original protocol. KT, EO, RO, YS, TS, AK, TK, and YM participated in refining the protocol. AK played a major role in the statistical analysis. KT, EO, TK, and NS contributed to developing the exercise program. EO and YM drafted the manuscript. All authors participated in, read, and approved the final manuscript.

Funding This study is supported by a National Cancer Center Research and Development Fund (30-A-17).

Competing interests EO has received research support from Nippon Suisan Kaisha, Ltd. YJM has received speaker fees from Pfizer, Mochida, Eli Lilly, Morinaga Milk, and NTT Data and is conducting collaborative research with Morinaga Milk. AK has received speaking fees from Chugai Pharmaceutical Co., Ltd. All other authors declare that they have no competing interests regarding this work.

Ethics approval. The protocol was approved by the Institutional Review Board of the National Cancer Center on 28 February 2019 (ID: 2018-274).

FIGURE LEGENDS

Figure 1. Flow diagram of study participants. HIIT, high-intensity interval training; ICT, information and communication technology.

Figure 2. Study design of the habit-b program (**h**ome-based high-intensity interval training **and** **b**ehavioral modification using **i**nformation and communication **t**echnology on cardiorespiratory fitness and exercise habits for sedentary **b**reast cancer survivors). HIIT, high-intensity interval training; ICT, information and communication technology.

Figure 3. Sample of high-intensity interval training using body weight exercise.

Figure 4. Brochure reminding participants about the importance of exercise and providing instructions about physical activity in daily life.

References

1. Denlinger CS, Sanft T, Baker KS, et al. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017;15(9):1140-63. doi: 10.6004/jnccn.2017.0146 [published Online First: 2017/09/07]
2. Public survey about cancer control in Japan. (*the Cabinet Office*); (<https://survey.gov-online.go.jp/h26/h26-gantaisaku/5.html>) (accessed on 2018/Aug./10)
3. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. *The New England journal of medicine* 2001;344(26):1997-2008. doi: 10.1056/nejm200106283442607 [published Online First: 2001/06/30]
4. Denlinger CS, Carlson RW, Are M, et al. Survivorship: Introduction and Definition: Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network : JNCCN* 2014;12(1):34-45.
5. Rock Cheryl L, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA: A Cancer Journal for Clinicians* 2012;62(4):242-74. doi: 10.3322/caac.21142
6. Hori M MT, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Japanese journal of clinical oncology* 2015;45(9):884-91.
7. Tao MH, Hainaut P, Marian C, et al. Association of prediagnostic physical activity with survival following breast cancer diagnosis: influence of TP53 mutation status. *Cancer Causes Control* 2013;24(12):2177-86. doi: 10.1007/s10552-013-0294-x [published Online First: 2013/09/27]
8. Rock CL, Flatt SW, Byers TE, et al. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. *J Clin Oncol* 2015;33(28):3169-76. doi: 10.1200/JCO.2015.61.1095 [published Online First: 2015/08/19]

- 1
2
3
4
5
6 9. Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role
7 in breast cancer rehabilitation. *Cancer* 2012;118(8 Suppl):2277-87. doi:
8 10.1002/cncr.27466 [published Online First: 2012/04/18]
9
- 10 10. Lee K, Kang I, Mortimer JE, et al. Effects of high-intensity interval training on
11 vascular function in breast cancer survivors undergoing anthracycline
12 chemotherapy: design of a pilot study. *BMJ Open* 2018;8(6):e022622. doi:
13 10.1136/bmjopen-2018-022622 [published Online First: 2018/07/02]
14
- 15 11. Saarto T, Sievanen H, Kellokumpu-Lehtinen P, et al. Effect of supervised and
16 home exercise training on bone mineral density among breast cancer
17 patients. A 12-month randomised controlled trial. *Osteoporosis*
18 *international : a journal established as result of cooperation between the*
19 *European Foundation for Osteoporosis and the National Osteoporosis*
20 *Foundation of the USA* 2012;23(5):1601-12. doi: 10.1007/s00198-011-
21 1761-4 [published Online First: 2011/09/06]
22
- 23 12. Peel JB, Sui X, Adams SA, et al. A prospective study of cardiorespiratory fitness
24 and breast cancer mortality. *Med Sci Sports Exerc* 2009;41(4):742-8. doi:
25 10.1249/MSS.0b013e31818edac7 [published Online First: 2009/03/12]
26
- 27 13. Peel AB, Thomas SM, Dittus K, et al. Cardiorespiratory fitness in breast cancer
28 patients: a call for normative values. *Journal of the American Heart*
29 *Association* 2014;3(1):e000432. doi: 10.1161/jaha.113.000432 [published
30 Online First: 2014/01/15]
31
- 32 14. Kuwabara M, Kuwabara R, Niwa K, et al. Different Risk for Hypertension,
33 Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body
34 Mass Index in Japanese and American Subjects. *Nutrients* 2018;10(8) doi:
35 10.3390/nu10081011 [published Online First: 2018/08/08]
36
- 37 15. Rogers LQ, Courneya KS, Anton PM, et al. Effects of the BEAT Cancer physical
38 activity behavior change intervention on physical activity, aerobic fitness,
39 and quality of life in breast cancer survivors: a multicenter randomized
40 controlled trial. *Breast Cancer Res Treat* 2015;149(1):109-19. doi:
41 10.1007/s10549-014-3216-z [published Online First: 2014/11/25]
42
- 43 16. Dolan LB, Campbell K, Gelmon K, et al. Interval versus continuous aerobic
44 exercise training in breast cancer survivors--a pilot RCT. *Support Care*
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 *Cancer* 2016;24(1):119-27. doi: 10.1007/s00520-015-2749-y [published
7 Online First: 2015/05/10]
8
- 9 17. Tanaka H, Desouza CA, Jones PP, et al. Greater rate of decline in maximal
10 aerobic capacity with age in physically active vs. sedentary healthy women.
11 *Journal of applied physiology (Bethesda, Md : 1985)* 1997;83(6):1947-53.
12 doi: 10.1152/jappl.1997.83.6.1947 [published Online First: 1998/02/14]
13
14 18. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death
15 in women: the St James Women Take Heart Project. *Circulation*
16 2003;108(13):1554-9. doi: 10.1161/01.Cir.0000091080.57509.E9
17 [published Online First: 2003/09/17]
18
19 19. Lee DC, Sui X, Ortega FB, et al. Comparisons of leisure-time physical activity and
20 cardiorespiratory fitness as predictors of all-cause mortality in men and
21 women. *British journal of sports medicine* 2011;45(6):504-10. doi:
22 10.1136/bjism.2009.066209 [published Online First: 2010/04/27]
23
24 20. Tabata I, Nishimura K, Kouzaki M, et al. Effects of moderate-intensity
25 endurance and high-intensity intermittent training on anaerobic capacity
26 and VO2max. *Med Sci Sports Exerc* 1996;28(10):1327-30. [published Online
27 First: 1996/10/01]
28
29 21. Batacan RB, Jr., Duncan MJ, Dalbo VJ, et al. Effects of high-intensity interval
30 training on cardiometabolic health: a systematic review and meta-analysis
31 of intervention studies. *British journal of sports medicine* 2017;51(6):494-
32 503. doi: 10.1136/bjsports-2015-095841 [published Online First:
33 2016/11/01]
34
35 22. Mallol M, Bentley DJ, Norton L, et al. Comparison of Reduced-Volume High-
36 Intensity Interval Training and High-Volume Training on Endurance
37 Performance in Triathletes. *International journal of sports physiology and*
38 *performance* 2019;14(2):239-45. doi: 10.1123/ijsp.2018-0359 [published
39 Online First: 2018/08/07]
40
41 23. Mugele H, Freitag N, Wilhelmi J, et al. High-intensity interval training in the
42 therapy and aftercare of cancer patients: a systematic review with meta-
43 analysis. *J Cancer Surviv* 2019 doi: 10.1007/s11764-019-00743-3
44 [published Online First: 2019/02/27]
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 24. McRae G, Payne A, Zelt JG, et al. Extremely low volume, whole-body aerobic-
7 resistance training improves aerobic fitness and muscular endurance in
8 females. *Applied physiology, nutrition, and metabolism = Physiologie*
9 *appliquee, nutrition et metabolisme* 2012;37(6):1124-31. doi:
10 10.1139/h2012-093 [published Online First: 2012/09/22]
11
12
13
14 25. Gresham G, Hendifar AE, Spiegel B, et al. Wearable activity monitors to assess
15 performance status and predict clinical outcomes in advanced cancer
16 patients. *npj Digital Medicine* 2018;1(1):27. doi: 10.1038/s41746-018-
17 0032-6
18
19
20
21 26. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for
22 AmericansPhysical Activity Guidelines for AmericansPhysical Activity
23 Guidelines for Americans. *JAMA* 2018;320(19):2020-28. doi:
24 10.1001/jama.2018.14854
25
26
27 27. Akechi T, Yamaguchi T, Uchida M, et al. Smartphone problem-solving and
28 behavioural activation therapy to reduce fear of recurrence among patients
29 with breast cancer (SMartphone Intervention to Lessen fear of cancer
30 recurrence: SMILE project): protocol for a randomised controlled trial. *BMJ*
31 *Open* 2018;8(11):e024794. doi: 10.1136/bmjopen-2018-024794 [published
32 Online First: 2018/11/11]
33
34
35
36
37 28. Gresham G, Schrack J, Gresham LM, et al. Wearable activity monitors in
38 oncology trials: Current use of an emerging technology. *Contemp Clin Trials*
39 2018;64:13-21. doi: 10.1016/j.cct.2017.11.002 [published Online First:
40 2017/11/14]
41
42
43
44 29. Bandura A. Health promotion by social cognitive means. *Health education &*
45 *behavior : the official publication of the Society for Public Health Education*
46 2004;31(2):143-64. doi: 10.1177/1090198104263660 [published Online
47 First: 2004/04/20]
48
49
50
51 30. Stacey FG, James EL, Chapman K, et al. A systematic review and meta-analysis
52 of social cognitive theory-based physical activity and/or nutrition behavior
53 change interventions for cancer survivors. *J Cancer Surviv* 2015;9(2):305-
54 38. doi: 10.1007/s11764-014-0413-z [published Online First: 2014/11/30]
55
56
57 31. Abedtash H, Holden RJ. Systematic review of the effectiveness of health-related
58 behavioral interventions using portable activity sensing devices (PASDs).
59
60

- 1
2
3
4
5
6 *Journal of the American Medical Informatics Association : JAMIA*
7 2017;24(5):1002-13. doi: 10.1093/jamia/ocx006 [published Online First:
8 2017/03/25]
9
- 10
11 32. Taylor HL, Buskirk E, Henschel A. Maximal oxygen intake as an objective
12 measure of cardio-respiratory performance. *Journal of applied physiology*
13 1955;8(1):73-80. doi: 10.1152/jappl.1955.8.1.73 [published Online First:
14 1955/07/01]
15
16
17 33. Whipp BJ, Davis JA, Torres F, et al. A test to determine parameters of aerobic
18 function during exercise. *Journal of applied physiology: respiratory,*
19 *environmental and exercise physiology* 1981;50(1):217-21. doi:
20 10.1152/jappl.1981.50.1.217 [published Online First: 1981/01/01]
21
22
23 34. Ross RM, Murthy JN, Wollak ID, et al. The six minute walk test accurately
24 estimates mean peak oxygen uptake. *BMC pulmonary medicine* 2010;10:31.
25 doi: 10.1186/1471-2466-10-31 [published Online First: 2010/05/28]
26
27
28 35. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian
29 Working Group for Sarcopenia. *J Am Med Dir Assoc* 2014;15(2):95-101. doi:
30 10.1016/j.jamda.2013.11.025 [published Online First: 2014/01/28]
31
32
33 36. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-
34 cancer-related lymphedema. *The New England journal of medicine*
35 2009;361(7):664-73. doi: 10.1056/NEJMoa0810118 [published Online
36 First: 2009/08/14]
37
38
39 37. Neil-Sztramko SE, Kirkham AA, Hung SH, et al. Aerobic capacity and upper limb
40 strength are reduced in women diagnosed with breast cancer: a systematic
41 review. *Journal of physiotherapy* 2014;60(4):189-200. doi:
42 10.1016/j.jphys.2014.09.005 [published Online First: 2014/12/03]
43
44
45 38. Van der Weijden-Van Doornik EM, Slot DE, Burtin C, et al. Grip Strength in
46 Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine
47 Therapy: Systematic Review. *Phys Ther* 2017;97(9):904-14. doi:
48 10.1093/ptj/pzx069 [published Online First: 2017/10/04]
49
50
51 39. Herrero F, San Juan AF, Fleck SJ, et al. Combined aerobic and resistance training
52 in breast cancer survivors: A randomized, controlled pilot trial.
53 *International journal of sports medicine* 2006;27(7):573-80. doi: 10.1055/s-
54 2005-865848 [published Online First: 2006/06/28]
55
56
57
58
59
60


- 1
2
3
4
5
6 40. Foley MP, Hasson SM. Effects of a Community-Based Multimodal Exercise
7 Program on Health-Related Physical Fitness and Physical Function in Breast
8 Cancer Survivors:A Pilot Study. *Integrative Cancer Therapies*
9 2016;15(4):446-54. doi: 10.1177/1534735416639716
10
11
12 41. Maruya K, Fujita H, Arai T, et al. Identifying elderly people at risk for cognitive
13 decline by using the 2-step test. *J Phys Ther Sci* 2018;30(1):145-49. doi:
14 10.1589/jpts.30.145
15
16 42. Organization WH. Global Physical Activity Surveillance [Available from:
17 <http://www.who.int/ncds/surveillance/steps/GPAQ/en/> accessed Aug. 10
18 2018.
19
20
21
22 43. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity
23 questionnaire (GPAQ) in assessing levels and change in moderate-vigorous
24 physical activity and sedentary behaviour. *BMC Public Health*
25 2014;14:1255. doi: 10.1186/1471-2458-14-1255 [published Online First:
26 2014/12/11]
27
28
29
30 44. Chu AH, Ng SH, Koh D, et al. Reliability and Validity of the Self- and Interviewer-
31 Administered Versions of the Global Physical Activity Questionnaire
32 (GPAQ). *PLoS One* 2015;10(9):e0136944. doi:
33 10.1371/journal.pone.0136944 [published Online First: 2015/09/04]
34
35
36
37 45. Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ):
38 nine country reliability and validity study. *Journal of physical activity &*
39 *health* 2009;6(6):790-804. [published Online First: 2010/01/28]
40
41
42 46. Vickberg SM. The Concerns About Recurrence Scale (CARS): a systematic
43 measure of women's fears about the possibility of breast cancer recurrence.
44 *Ann Behav Med* 2003;25(1):16-24.
45
46
47 47. Momino K, Akechi T, Yamashita T, et al. Psychometric Properties of the
48 Japanese Version of the Concerns About Recurrence Scale (CARS-J).
49 *Japanese Journal of Clinical Oncology* 2014;44(5):456-62. doi:
50 10.1093/jjco/hyu032
51
52
53 48. Muramatsu K, Miyaoka H, Kamijima K, et al. The patient health questionnaire,
54 Japanese version: validity according to the mini-international
55 neuropsychiatric interview-plus. *Psychological reports* 2007;101(3 Pt
56
57
58
59
60

- 1
2
3
4
5
6 1):952-60. doi: 10.2466/pr0.101.3.952-960 [published Online First:
7 2008/02/01]
8
9
10 49. Okajima I, Nakajima S, Kobayashi M, et al. Development and validation of the
11 Japanese version of the Athens Insomnia Scale. *Psychiatry and clinical*
12 *neurosciences* 2013;67(6):420-25. doi: 10.1111/pcn.12073 [published
13 Online First: 2013/08/05]
14
15 50. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation
16 of an instrument based on ICD-10 criteria. *Journal of psychosomatic research*
17 2000;48(6):555-60.
18
19 51. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol
20 Group. *Annals of medicine* 2001;33(5):337-43. [published Online First:
21 2001/08/09]
22
23 52. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set:
24 the case of Japan. *Health economics* 2002;11(4):341-53. doi:
25 10.1002/hec.673 [published Online First: 2002/05/15]
26
27 53. Liu G, Muhlhausler BS, Gibson RA. A method for long term stabilisation of long
28 chain polyunsaturated fatty acids in dried blood spots and its clinical
29 application. *Prostaglandins, leukotrienes, and essential fatty acids*
30 2014;91(6):251-60. doi: 10.1016/j.plefa.2014.09.009 [published Online
31 First: 2014/12/03]
32
33 54. Scribbans TD, Vecsey S, Hankinson PB, et al. The Effect of Training Intensity on
34 VO2max in Young Healthy Adults: A Meta-Regression and Meta-Analysis.
35 *International journal of exercise science* 2016;9(2):230-47. [published
36 Online First: 2016/05/18]
37
38 55. Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise
39 training in postmenopausal breast cancer survivors: cardiopulmonary and
40 quality of life outcomes. *J Clin Oncol* 2003;21(9):1660-8. doi:
41 10.1200/jco.2003.04.093 [published Online First: 2003/05/02]
42
43 56. Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-
44 related decline across the breast cancer survivorship continuum. *J Clin*
45 *Oncol* 2012;30(20):2530-7. doi: 10.1200/JCO.2011.39.9014 [published
46 Online First: 2012/05/23]
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 57. Okumatsu K, Tsujimoto T, Wakaba K, et al. Physical fitness level in Japanese
7 breast cancer survivors. *Japanese Journal of Physical Fitness and Sports*
8 *Medicine* 2018;67(2):169-76. doi: 10.7600/jspfsm.67.169
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



190x191mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



190x101mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



3 min and 10 sec Warm up	Squat	rest	Lunge	rest	Squat	rest	Lunge	rest	Squat	rest	Lunge	rest	Squat	rest	Lunge	3 min cool down
	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	

10 min

184x43mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



NCC 法政大学
habit-B

1人ではなくみんなで頑張りましょう!

【TSUKIDA habit-B プロジェクト】
癌後、乳がんや乳がんサバイバー向けの運動習慣を身につけるための運動プログラムを開発しています。

〒104-8504 東京都中央区豊洲4-1-1
https://www.ncc.go.jp/StepB/06main/06habits_bproject/01/01/010178020.html
番号：17000000 habit-Bプロジェクト
実行責任者：中野 悠子 実行委員：中野 悠子 法政大学 健康増進部



Let's training

乳がんサバイバーのあなたへ

体力向上のためのトレーニング

自宅で簡単・安心トレーニングのご案内



こんなことはありませんか？

<ul style="list-style-type: none"> <input type="checkbox"/> 体力の低下を感じている <input type="checkbox"/> 疲れやすくなる <input type="checkbox"/> そろそろ運動をはじめてみたい 	<ul style="list-style-type: none"> <input type="checkbox"/> いつもの体力に戻したい <input type="checkbox"/> 一人でトレーニングは不安だ <input type="checkbox"/> 毎日を楽しんで過ごしたい
---	---

毎日の生活に運動を取り入れましょう!

疲れにくいカラダをつくる4つの運動

心臓機能を高く維持することは疲れにくいカラダをつくり、乳がんサバイバーにとってきわめて重要です。下記の運動は、ふとももやおしりの筋肉を鍛錬しながら丁寧に実施することで運動中に心拍数を上昇させて心臓機能を向上させます。さらにこれらの運動は肥満やサルコペニアの予防にも役立ちます。

Step 1



Point
膝よりつま先が伸びないように注意してください。

Step 2



Point
膝よりつま先が伸びないように注意してください。

Step 3



Point
膝よりつま先が伸びないように注意してください。

Step 4



Point
肘が肩の真下に来るように注意してください。

<p>スクワット</p> <p>足を肩幅からやや広めに並び、お尻を後ろに突き出すながら、上半身を倒さないように膝の角度が伸びないように注意してください。</p>	<p>フロントランジ</p> <p>片足ずつ足を前に出します。両足を伸ばして、膝が出た側の膝がつま先より前に出ないように膝を曲げましょう。</p>	<p>スクーターズランジ</p> <p>両足のジャンプ動作ができません。膝へ落とすは股関節を伸ばすように注意しましょう。腰骨の動き、膝とつま先の動きを確認して、両足同時にスクーターズランジにしましょう。</p>	<p>プッシュアップ</p> <p>両足を肩幅より狭く開く運動です。 ①しゃがみこんで立ち上がり ②手を肩幅より狭く開いて足を肩幅に伸ばして、両足で足先の姿勢をとる ③両肘を肩の真下に来るように注意して、しゃがみこんで立ち上がり ④両肘を肩の真下に来るように注意して、しゃがみこんで立ち上がり</p>
---	--	--	---

166x236mm (96 x 96 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
Funding	4	Sources and types of financial, material, and other support
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	--

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how
13			
14			
15		17b	If blinded, circumstances under which unblinding is permissible, and
16			procedure for revealing a participant's allocated intervention during
17			the trial
18			

Methods: Data collection, management, and analysis

21			
22	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
23	methods		trial data, including any related processes to promote data quality (eg,
24			duplicate measurements, training of assessors) and a description of
25			study instruments (eg, questionnaires, laboratory tests) along with
26			their reliability and validity, if known. Reference to where data
27			collection forms can be found, if not in the protocol
28			
29			
30		18b	Plans to promote participant retention and complete follow-up,
31			including list of any outcome data to be collected for participants who
32			discontinue or deviate from intervention protocols
33			
34	Data	19	Plans for data entry, coding, security, and storage, including any
35	management		related processes to promote data quality (eg, double data entry;
36			range checks for data values). Reference to where details of data
37			management procedures can be found, if not in the protocol
38			
39			
40	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
41	methods		Reference to where other details of the statistical analysis plan can be
42			found, if not in the protocol
43			
44			
45		20b	Methods for any additional analyses (eg, subgroup and adjusted
46			analyses)
47			
48		20c	Definition of analysis population relating to protocol non-adherence
49			(eg, as randomised analysis), and any statistical methods to handle
50			missing data (eg, multiple imputation)
51			

Methods: Monitoring

52			
53			
54	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
55			and reporting structure; statement of whether it is independent from
56			the sponsor and competing interests; and reference to where further
57			details about its charter can be found, if not in the protocol.
58			Alternatively, an explanation of why a DMC is not needed
59			
60			

1		21b	Description of any interim analyses and stopping guidelines, including
2			who will have access to these interim results and make the final
3			decision to terminate the trial
4			
5			
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and
7			spontaneously reported adverse events and other unintended effects
8			of trial interventions or trial conduct
9			
10			
11	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and
12			whether the process will be independent from investigators and the
13			sponsor
14			

15 Ethics and dissemination

16			
17	Research ethics	24	Plans for seeking research ethics committee/institutional review board
18	approval		(REC/IRB) approval
19			
20			
21	Protocol	25	Plans for communicating important protocol modifications (eg,
22	amendments		changes to eligibility criteria, outcomes, analyses) to relevant parties
23			(eg, investigators, REC/IRBs, trial participants, trial registries, journals,
24			regulators)
25			
26	Consent or assent	26a	Who will obtain informed consent or assent from potential trial
27			participants or authorised surrogates, and how (see Item 32)
28			
29		26b	Additional consent provisions for collection and use of participant data
30			and biological specimens in ancillary studies, if applicable
31			
32			
33	Confidentiality	27	How personal information about potential and enrolled participants will
34			be collected, shared, and maintained in order to protect confidentiality
35			before, during, and after the trial
36			
37	Declaration of	28	Financial and other competing interests for principal investigators for
38	interests		the overall trial and each study site
39			
40			
41	Access to data	29	Statement of who will have access to the final trial dataset, and
42			disclosure of contractual agreements that limit such access for
43			investigators
44			
45	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for
46	post-trial care		compensation to those who suffer harm from trial participation
47			
48	Dissemination	31a	Plans for investigators and sponsor to communicate trial results to
49	policy		participants, healthcare professionals, the public, and other relevant
50			groups (eg, via publication, reporting in results databases, or other
51			data sharing arrangements), including any publication restrictions
52			
53			
54		31b	Authorship eligibility guidelines and any intended use of professional
55			writers
56			
57		31c	Plans, if any, for granting public access to the full protocol, participant-
58			level dataset, and statistical code
59			
60			

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

BMJ Open

Effect of home-based high-intensity interval training and behavioral modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: the habit-B study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030911.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Jun-2019
Complete List of Authors:	<p>Tsuji, Katsunori; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Ochi, Eisuke; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences; Hosei University, Faculty of Bioscience and Applied Chemistry Okubo, Ryo; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Shimizu, Yoichi; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Kuchiba, Aya; National Cancer Center Japan, Division of Biostatistical Research, Center for Public Health Sciences; National Cancer Center Japan, Biostatistics Division, Center for Research Administration and Support Ueno, Taro; SUSMED, Inc. Shimazu, Taichi; National Cancer Center Japan, Division of Prevention, Center for Public Health Sciences Kinoshita, Takayuki; National Cancer Center Hospital, Department of Breast Surgery Sakurai, Naomi; Cancer Solutions Matsuoka, Yutaka; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences</p>
Primary Subject Heading:	Sports and exercise medicine
Secondary Subject Heading:	Mental health, Oncology
Keywords:	Breast tumours < ONCOLOGY, SPORTS MEDICINE, PREVENTIVE MEDICINE, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open Study protocols

Effect of home-based high-intensity interval training and behavioral modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: the habit-B study protocol for a randomized controlled trial

Katsunori Tsuji^{1*}, Eisuke Ochi^{1, 2*}, Ryo Okubo¹, Yoichi Shimizu¹, Aya Kuchiba^{3,4}, Taro Ueno⁵, Taichi Shimazu⁶, Takayuki Kinoshita⁷, Naomi Sakurai⁸, Yutaka J. Matsuoka¹

1. Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
2. Faculty of Bioscience and Applied Chemistry, Hosei University, Tokyo, Japan
3. Division of Biostatistical Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
4. Biostatistics Division, Center for Research Administration and Support, National Cancer Center Japan, Tokyo, Japan
5. SUSMED, Inc., Tokyo, Japan
6. Division of Prevention, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
7. Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan
8. Cancer Solutions, Tokyo, Japan

* These two authors contributed equally to this work

Corresponding author

Yutaka J. Matsuoka, MD, PhD

Division of Health Care Research, Center for Public Health Sciences, National

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cancer Center Japan, Tokyo, Japan

E-mail address: yumatsuo@ncc.go.jp, Phone: +81-3-3547-5201 ext. 3382

For peer review only

ABSTRACT

Introduction

Maintaining high levels of physical activity not only helps to maintain and improve physical health and quality of life, but also plays a role in reducing adverse effects due to cancer treatments. Moreover, a greater degree of cardiorespiratory fitness is associated with reduced risk of all-cause mortality. However, there are no home-based programs for improving cardiorespiratory fitness using body weight exercises for breast cancer survivors. This study will assess the efficacy of the newly developed habit-B program on maximum oxygen uptake compared with treatment as usual. The effects of this program on exercise habits, level of physical activity, physical fitness, and subjective indices will also be investigated.

Methods and analysis

This is a 12-week, parallel-group, single blind, randomized controlled trial. Allocation will be managed by a central server using a computer-generated random allocation sequence provided by an independent data center. Participants will be assigned to the habit-B Program (high-intensity interval training exercise, exercise counseling + guidance, home-based exercise support using information and communication technology, and a wearable device) or treatment as usual with a wearable device. Subjects will be sedentary women aged 20 to 59 years who have received breast surgery in the past 2 to 13 months after diagnosis of invasive breast cancer (Stage I-IIa) and have never received chemo-therapy except for

1
2
3
4
5
6 hormone therapy. The primary endpoint is the change in peak oxygen uptake
7
8 (VO_{2peak} ; mL/kg/min) between the groups after 12 weeks of intervention.
9

10 **Ethics and dissemination**

11
12
13 The study protocol was approved by the Institutional Review Board of the National
14
15
16 Cancer Center Japan on 28 February 2019 (ID: 2018-347). The findings will be
17
18
19 disseminated through peer reviewed publications and conference presentations.
20

21
22
23 **Trial status** Study enrolment, intervention, and data collection are ongoing. The
24
25
26 estimated end date for this study is on March 31, 2021.
27

28
29 **Trial registration number** UMIN000036400; Pre-results.
30

31 **Strengths and limitations of this study**

- 32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. This clinical trial will be the world's first home-based HIIT program using ICT to increase cardiorespiratory fitness in sedentary breast cancer survivors.
 2. The habit-B program is designed based on the theory of Bandura for sedentary breast cancer survivors to develop exercise habits.
 3. Collaborative work with professionals in the field of clinical oncology, exercise science, mental health, rehabilitation, public health, nursing, and cancer survivors constitutes a new model for cancer survivorship care.
 4. We cannot rigorously exclude breast cancer survivors who may have exercise habits because the definition of sedentary subjects will be based on self-report.

INTRODUCTION

1
2
3
4
5
6 Breast cancer, which is one of the most common cancers affecting women,
7
8 newly affects over 86,000 women each year¹. It is recommended that cancer
9
10 survivors acquire and maintain healthy behaviors to extend survival, such as
11
12 staying reasonably fit through appropriate physical exercise and having a healthy
13
14 diet ². High levels of physical activity not only help to maintain and improve
15
16 physical health and quality of life (QOL), but also play a role in reducing short- and
17
18 long-term side effects of cancer treatment. The American Cancer Society guidelines
19
20 recommend a minimum of 150 min moderate physical activity or 75 min intensive
21
22 physical activity per week, in addition to usual physical activity in daily life³, and
23
24 the Japan Breast Cancer Society's Clinical Guidelines for Breast Cancer strongly
25
26 recommend maintaining a high level of physical activity^{4 5}.

27
28
29
30
31
32
33 The ENERGY Trial, an early and representative study conducted in the US,
34
35 demonstrated the effectiveness of a home exercise program and nutritional advice
36
37 to promote weight loss among breast cancer survivors⁶. However, because the
38
39 proportion of overweight adults in Japan is lower than that in the US⁷, it is not
40
41 appropriate to adopt the US-developed program in Japan. It would appear suitable
42
43 though to develop intervention around measurements of VO_{2peak} , the globally
44
45 important health indicator of cardiorespiratory fitness ^{8 9}.

46
47
48
49
50
51 VO_{2peak} decreases with age, and a meta-analysis has suggested that women
52
53 who are sedentary have a decrease of 3.2 mL/kg/min over 10 years¹⁰. A cohort
54
55 study suggested that the all-cause mortality rate decreased by 17% for each 1
56
57 metabolic equivalent (MET) increase (3.5 mL/kg/min) in VO_{2peak} for women¹¹. A
58
59
60

1
2
3
4
5
6 systematic review demonstrated that the median VO_{2peak} of breast cancer
7
8 survivors not receiving chemotherapy was lower than that of healthy sedentary
9
10 women (25.3 mL/kg/min vs. 29.7 mL/kg/min)¹². In a 16-year follow-up study of
11
12 breast cancer survivors¹², hazard ratios were 0.67 for the moderate VO_{2peak} group
13
14 (8.5 METs) and 0.45 for the high group (11.1 METs) compared with the low VO_{2peak}
15
16 group (6.7 METs). In this report, the mortality rate was reduced by maintaining a
17
18 VO_{2peak} of 8 METs or above¹². Against this background, it is necessary to develop an
19
20 exercise program that will increase VO_{2peak} in breast cancer survivors.
21
22
23
24
25

26 When considering how to increase VO_{2peak} , research has advanced in recent
27
28 years with the use of HIIT for athletes and sedentary populations¹³⁻¹⁵. HIIT allows
29
30 subjects to exercise at vigorous intensity within 10 min, resulting in improved
31
32 cardiorespiratory fitness^{9 16}. A recent systematic review showed, based on the
33
34 findings of 12 studies of HIIT conducted in supervised experimental settings, that
35
36 HIIT appeared to be more beneficial than treatment as usual for improving
37
38 physical fitness and health-related outcomes in cancer survivors during any stage
39
40 of treatment and aftercare¹⁶. To our knowledge, only one study has evaluated
41
42 changes in cardiorespiratory fitness following a home-based HIIT program, which
43
44 involved healthy young women¹⁷. Given that no home-based HIIT programs with
45
46 body weight exercises have been reported for breast cancer survivors to date, it is
47
48 necessary to develop such programs and examine their efficacy and feasibility.
49
50
51
52
53
54

55 Recent emerging technologies such as smartphone applications (apps) and
56
57 wearable devices are promising tools for the monitoring of cancer patients' daily
58
59
60

1
2
3
4
5
6 activity levels and for facilitating coaching, self-monitoring, feedback, and
7
8 encouragement to exercise^{18,19}. Apps²⁰ and wearable devices²¹ are being used for
9
10 both subjective and objective measures in the field of clinical oncology. However,
11
12 further investigations are needed of their potential utility in objective evaluations
13
14 of physical activity as well as in lifestyle modification and maintenance and
15
16 enhancement of QOL in real-world settings.
17
18
19

20
21 The aim of this study is to investigate the effect of the newly developed
22
23 habit-B program, comprising **h**ome-based high-intensity interval training **a**nd
24
25 **b**ehavioral modification using **i**nformation and communication **t**echnology on
26
27 cardiorespiratory fitness and exercise habits for sedentary **b**reast cancer
28
29 survivors. We will investigate whether the habit-B program improves VO_{2peak}
30
31 compared with a control group as well as investigate the safety and feasibility of
32
33 program. The secondary objectives are to investigate the effect of this program on
34
35 exercise habits, physical activity level, physical function, and subjective measures.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

Trial design

In this study 12-week, parallel-group, single blind, randomized controlled trial (Figure 1), participants will be randomly assigned to intervention either with the habit-B program (HIIT exercise, exercise counseling + guidance, home-based exercise support using ICT, and a wearable device) or treatment as usual with a wearable device (Fitbit Versa smart watch; Fitbit Inc., San Francisco, CA). An independent data center will provide computer-generated random allocation. Participants will be assigned by the minimization method, a form of dynamic randomization, using two prognostic factors: VO_{2peak} and age. Based on the allocation sequences, the contents of the app that participants use during the trial will be assigned automatically to either the habit-B program or control.

Participants

The eligibility criteria for participants are as follows: (1) female, aged between 20 and 59 years at diagnosis (stages I-IIa); (2) diagnosed with invasive breast cancer within 2 to 13 months after surgery; (3) not requiring cancer chemotherapy aside from hormone therapy; (4) currently engages in not more than moderate intensity exercise for 30 min on 2 separate days per week (total of 60 min), which is based on the National Health and Nutrition Survey Japan²²; (5) ability to complete an electronic patient reported outcome (e-PRO) questionnaire via a smartphone; (6) consent to trial participation obtained in writing from the

1
2
3
4
5
6 patient themselves; and (7) ability to read, write, and understand Japanese. The
7
8 exclusion criteria are as follows: (1) judged to have severely reduced cognitive
9
10 function by a primary physician; (2) exercise judged to be risky by a primary
11
12 physician; (3) history of smoking within the previous 12 months; (4) body mass
13
14 index of 30 or above; (5) abnormal electrocardiogram in preoperative testing,
15
16 resting heart rate (HR) below 60 beats/min or above 100 beats/min, or stage III
17
18 hypertension or above (diastolic blood pressure over 110 mmHg or systolic blood
19
20 pressure over 180 mmHg); and (6) judged unfit for the trial by a primary physician
21
22 for other reasons.
23
24
25
26
27
28
29
30

31 **Interventions**

32
33 This will be a randomized, single-blind study. Participants will be
34
35 enrolled and assigned using an electronic data capture system with an app. The
36
37 protocol intervention will be started within 21 days of enrollment. If for some
38
39 reason the start is delayed beyond 21 days, the reason will be entered into the
40
41 electronic Case Report Form (eCRF). If it is determined that the intervention
42
43 cannot be started, the details will be noted in the eCRF as “protocol intervention
44
45 stopped.”
46
47
48
49
50
51

52 53 The habit-B program group

54
55 The habit-B program (Figure 2) comprises home-based exercise support
56
57 utilizing 6 weeks of exercise counseling/exercise guidance (once per week, 6 times
58
59
60

1
2
3
4
5
6 total, 30 min per session) and 12 weeks of ICT interventions, which are provided
7
8 with personalized e-mail (once per week, 12 times in total), and a newly developed
9
10 exercise app (during each exercise session, shown in Figure 3). Participants will be
11
12 encouraged to complete the following program HIIT using specific body weight
13
14 exercises for one 10-min training session 3 times a week for 12 weeks (total of 36
15
16 sessions during the trial period, as shown in Figures 2 and 4): (1) one bout of 10-
17
18 min exercises; (2) a total of 10 min exercise, comprising a 3-min warm-up, 4-min
19
20 training (8 sets of 20 s exercise + 10 s rest), and a 3-min cool-down; (3) these
21
22 training exercises are designed to increase in intensity each week; and (4) the
23
24 details of these exercises are divided into three stages according to
25
26 cardiorespiratory fitness (VO_{2peak}) at Week 0 and the contents of training are
27
28 designed to increase physical strength incrementally in accordance with the
29
30 individual's level of strength. In addition, we will continue to follow up on the
31
32 between-group differences in e-PRO data of change from baseline to 24 and 36
33
34 weeks post-intervention.
35
36
37
38
39
40
41
42
43

44 The social cognitive theory proposed by Bandura et al. may be helpful to
45
46 apply when considering interventions for behavioral change²³, chiefly in that it
47
48 affords a framework for understanding the underlying reasons for making and
49
50 maintaining health behaviors²⁴. Its key concepts involve (1) understanding of health
51
52 risks and benefits, (2) perceived self-efficacy of being able to control one's own
53
54 health habits, (3) projected costs and benefits or expected outcomes, (4) specified
55
56 health goals with short- and long-term intentions to engage in the behavior, (5)
57
58
59
60

1
2
3
4
5
6 perceived facilitators and social support, and (6) barriers to instituting change^{23 24}.

7
8 In the present study, we developed the exercise program applying the first 5
9
10 concepts.

11
12
13 We will also provide the participant a brochure as a reminder to exercise and
14
15 will check the type of physical activity they engage in in daily life (Figure 5). When
16
17 developing the habit-B program, we collaborated closely with exercise scientists,
18
19 oncologists, physical therapists, nurses, mental health practitioners, and breast
20
21 cancer survivors.
22
23
24
25
26
27

28 Control group

29
30 The control group will be provided a wearable device and setup support
31
32 at the start of intervention. Self-monitoring using the wearable device will be
33
34 recommended during the trial period. While there are no reports of increasing
35
36 VO_{2peak} with the use of a wearable device alone, other reports have ruled out their
37
38 efficacy with regard to effects on exercise habits²⁵. In this study, the wearable
39
40 devices are used only to monitor physical activity in the control group.
41
42
43
44
45
46
47

48 PROCEDURE

49 Data collection, management, monitoring, and auditing

50
51 We will collect all data except qualitative interview data, blood samples,
52
53 fecal samples, and medical economic costs through the e-PRO system. Those who
54
55 provide consent will be enrolled in the app-based e-PRO system on their
56
57
58
59
60

1
2
3
4
5
6 smartphone. If the entered data is insufficient, enrollment will not be accepted
7
8 until all fields are completed at baseline. The electronic data capture system will be
9
10 used for data management and central monitoring. Because this exercise program
11
12 will not be invasive, there is no need to establish a data monitoring committee or
13
14 to complete auditing in this study.
15
16
17
18
19
20

21 **Random assignment and assignment adjustment factors**

22
23 After enrollment and the additional input of the VO_{2peak} value, patients
24
25 will be randomly assigned. In the process of random assignment, VO_{2peak} (obtained
26
27 from the baseline measurement performed after obtaining informed consent) and
28
29 age will be used as assignment adjustment factors, and automatic assignment will
30
31 be performed using the data center's assignment feature. Only the measurer will
32
33 be blinded in this study, because interventions differ for the intervention group
34
35 and control group.
36
37
38
39
40
41
42
43

44 **Dataset availability**

45
46 The data sharing policy in this study is defined with reference to the
47
48 example proposed by the International Committee of Medical Journal Editors
49
50 (ICMJE): Individual participant data will be made publicly available for a 5-year
51
52 period through the University Hospital Medical Information Network – Individual
53
54 Case Data Repository (UMIN-ICDR) (<https://www.umin.ac.jp/icdr/index-j.html>).
55
56
57
58
59
60

Concomitant treatments

There are no regulated concomitant therapies or supportive therapies in this study.

Stopping rules for participants

Situations in which the intervention protocol is terminated for any of the following reasons will be defined as stopping of the protocol intervention: (1) dropping out due to withdrawal of consent or inability to measure the primary endpoint (VO_{2peak}); (2) if a primary physician deems it necessary to stop the protocol intervention for a participant due to adverse events such as stress; (3) death of the patient during the protocol intervention period; (4) sudden worsening of the participant's condition after enrollment or discovery of a protocol violation or ineligibility. A researcher will report the reason for stopping the protocol intervention to the data center. In this event, as long as consent is not withdrawn, follow-up including the questionnaire survey will be continued.

Stopping of the assessment

Situations in which the participant declines assessment will effectively stop the assessment. A researcher will confirm the possibility of implementing the remaining parts of the intervention and follow-up with the participant. Stopping of the assessment will be recorded along with the details of the reason for stopping.

1
2
3
4
5
6 As a rule, the remaining aspect of follow-up will be implemented as stipulated per
7
8 protocol.
9

10 11 12 13 **Assessment measures**

14
15
16 Table 1 shows the outcome measurement schedule.
17

18
19
20
21 Primary outcome measure: Cardiorespiratory fitness (VO_{2peak})
22

23
24 VO_{2peak} is the maximum oxygen uptake observed during exercise
25
26 tolerance testing and is used as an indicator of cardiorespiratory fitness^{26 27}. For
27
28 each participant, VO_{2peak} will be measured using the incremental multistage load
29
30 method with a bicycle ergometer (Ergomedic 828E, Monark, Stockholm, Sweden)
31
32 at 60 revolutions per min (rpm). The test will begin at 0.5 kp and increase by 0.25
33
34 kp per min until exhaustion. When the participant's pedal rotation speed drops
35
36 below 55 rpm 3 times, the test will be deemed concluded. Respiratory gases will be
37
38 analyzed using an automatic gas analyzer (Air Monitor AE-310S, Minato Medical
39
40 Science Co., Ltd., Osaka, Japan). Rated perceived exertion and HR will be recorded
41
42 after 45 s in each stage. The maximum value of VO_2 observed during exercise will
43
44 be used as the VO_{2peak} .
45
46
47
48
49
50
51
52

53 Secondary outcome measures

54
55
56 *Physical function*
57
58
59
60

1
2
3
4
5
6 An alternative indicator of VO_{2peak} the 6-min walk test (m), will be
7
8 performed²⁸. Walking speed (m/s), a diagnostic criterion for sarcopenia, will also
9
10 be measured. A 5-m section in the middle of an 11-m line will be measured to
11
12 calculate walking speed²⁹. One-repetition maximum for leg press, which reflects
13
14 muscle strength in the lower body, will be assessed using a leg press machine
15
16 (Powertec Leg Press P-LP16; Powertec, Paramount, CA)^{30 31}. After a thorough
17
18 warm-up, measurements will be performed by incrementally increasing the load
19
20 until a weight, which can be lifted only once, is reached. Load will be increased by
21
22 two levels at a time. Grip strength (TKK 5401 Grip-D; Takei, Niigata, Japan) will
23
24 also be measured^{31 32}. The chair stand test, which reflects combined leg strength
25
26 for the lower limbs as a whole, will be performed^{31 33}. Participants will sit and
27
28 stand from a chair for 10 s and the number of chair stands will be measured. The
29
30 timed up and go test, which is used in clinical settings as an assessment of
31
32 functionality as well as muscular strength, will also be performed³¹. The functional
33
34 reach test, which as a method of assessing dynamic balance is considered an
35
36 indicator of expected fall risk, will also be performed³⁴. While keeping the hand at
37
38 the same height, the participant will extend their arm forward as far as possible,
39
40 without moving the feet, to make a mark at the farthest point they can reach.
41
42 Lifting the heels and standing on tiptoe is allowed. The two-step test will also be
43
44 performed³⁵. This test comprehensively assesses ability to walk, including leg
45
46 strength, balance, and flexibility. Based on bioelectrical impedance analysis, a body
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 composition meter (MC-780A-N, TANITA, Japan) will be used to send a weak
7
8 electrical current through the body via electrodes.
9

10 11 12 13 *Physical activity level*

14
15
16 The Global Physical Activity Questionnaire (GPAQ) was developed in
17
18 2002 as an internationally standardized questionnaire for surveying physical
19
20 activity level. The GPAQ is widely used in policy development by the World Health
21
22 Organization³⁶⁻³⁸. The face validity of the Japanese version has been confirmed³⁹.
23
24 In addition, as an objective measure of physical activity during the research period,
25
26 resting HR, steps, distance, calorie expenditure, and the duration of each sleep
27
28 stage as well as wake up time will be measured using an activity monitor and
29
30 logged for 24-h periods (Fitbit versa, Fitbit Inc., San Francisco, CA). Maximum HR
31
32 during exercise will also be measured to confirm whether the intensity of the
33
34 exercise being implemented is appropriate. The accurately measured group will be
35
36 defined as the group who wears the Fitbit versa at least 60% of the time during the
37
38 12-week intervention period.
39
40
41
42
43
44
45
46
47
48

49 *Subjective measures*

50
51 Fear of cancer recurrence (FCR) will be assessed by the overall fear index
52
53 score on the Concerns About Recurrence Scale^{40 41}. This instrument comprises 4
54
55 items scored on a 6-point Likert scale (range, 1–6), with a higher score indicating
56
57 worse FCR. Depression will be assessed using the Patient Health Questionnaire-9
58
59
60

1
2
3
4
5
6 42. Fatigue will be assessed by the Cancer Fatigue Scale. Sleep will be assessed by
7
8 the Athens Insomnia Scale^{43 44}. Health-related QOL will be assessed using the
9
10 EuroQol 5 Dimensions questionnaire^{45 46}.
11
12
13
14
15

16 *Biological assessments*

17
18 To assess changes in gut microbiota, intestinal metabolites, and intestinal
19 immunity⁴⁷, a 1-g fecal sample will be obtained at baseline and at 12 weeks. Blood
20
21 compositions of n-3 polyunsaturated fatty acids⁴⁸ will be assessed from capillary
22
23 dried blood spot samples (approximately 80 μ L) at baseline⁴⁹.
24
25
26
27
28
29
30

31 *Medical economic costs*

32
33 For cost-benefit analysis, the number of staff, working hours, labor costs,
34
35 equipment costs, office expenses, number of unexpected medical consultations,
36
37 direct medical costs, and costs of other medical services used will be obtained.
38
39
40
41
42
43

44 **Harms**

45
46 The intervention in this research will potentially place stress on
47
48 participants physically and in terms of their time, because it will take
49
50 approximately 1 h and 30 min. There will also be temporary exhaustion, although
51
52 individual differences will be considered in exercise implementation. There are no
53
54 financial risks associated with participation in the study.
55
56
57
58
59
60

Compensation

If participants develop unexpected health issues due to study participation during or after completion of the study, treatment will be provided appropriately in the same way as standard medical care. Medical expenses at that time will be handled within the medical insurance to which the participant is enrolled. No financial compensation, except for providing the wearable device, will be given in this study.

DATA ANALYSIS

The primary endpoint, VO_{2peak} , will be calculated as follows. Measurements will be taken at the start of the intervention (0 week) and at the conclusion of the intervention (12 weeks). The analysis set for primary analyses will consist of all randomized subjects. Our primary analysis is intention-to-treat analysis and patients without outcome data will be excluded from the analyses. After completing primary endpoint data locking, analyses centering on the primary endpoint will be performed. The objective of primary analysis in this study is to investigate whether the habit-B program group (trial treatment group) surpasses the group receiving treatment as usual (control) in VO_{2peak} , the primary endpoint. One-sided tests will be used, because, if the trial intervention group is inferior to the control group, it is not important in this trial whether that difference is statistically significant. The trial will adopt a one-sided significance level of 2.5%. A between-groups comparison will be performed using an independent two-sample

1
2
3
4
5
6 t-test to determine the significance of amount of change in VO_{2peak} (mL/kg/min)
7
8 from 0 week to 12 weeks (after intervention completion) between the trial
9
10 intervention and the control groups. Secondary endpoint analyses will be
11
12 performed with the goal of supplementing the primary analyses. The detailed
13
14 methods for supplementary analyses will be specified in the Statistical Analysis
15
16 Plan before the study data is fixed. Once all data has been locked following
17
18 conclusion of the primary analysis period and follow-up, final analyses will be
19
20 performed.
21
22
23
24
25
26
27
28

29 **Sample size estimation**

30
31 The main hypothesis of this study is that the intervention group will
32
33 significantly surpass the control group in terms of the amount of change in VO_{2peak}
34
35 from 0 week to 12 weeks. Regarding the clinical significance of the results of an
36
37 exercise program, it is common to use an increase of 10% in VO_{2peak} to evaluate the
38
39 effects of an exercise program⁵⁰. As such, an increase of 10% from VO_{2peak} at the
40
41 start of exercise has been established for this trial. According to a previous study of
42
43 intervention similar to that in the present study⁵¹, the standard deviation for the
44
45 VO_{2peak} of the intervention group was 2.6 mL/kg/min. Based on the above
46
47 hypothesis, by estimating the number of subjects required for a one-sided 2.5%
48
49 and a power of 80% in the analysis, 28 individuals per group are necessary for a
50
51 total of 56 in both groups (SAS 9.4 software; SAS Institute Inc., Cary, NC). With the
52
53 estimation that 4 participants will drop out, enrollment of 60 patients is planned.
54
55
56
57
58
59
60

Study period

The study period of this trial will be from April 2019 to March 2021; the participant entry period will be from April 2019 to March 2020. Study enrolment, intervention, and data collection are ongoing.

PATIENT AND PUBLIC INVOLVEMENT STATEMENT

This study protocol was designed with the involvement of a breast cancer survivor who participated in this study as a researcher and coauthor. She discussed issues with other survivors in instances where survivors' preferences and opinions should be considered. In the process of creating the habit-B program, we conducted a preliminary confirmation of the feasibility and safety of this program in 5 breast cancer survivors.

ETHICAL CONSIDERATIONS AND DISSEMINATION

The protocol was approved by the Institutional Review Board of the National Cancer Center Research Ethical Review Committee on 28 February 2019 (ID: 2018-274). The results obtained will be submitted for publication in a peer-reviewed international journal, and the main relevant findings will be presented at conferences.

DISCUSSION

An excellent review by Shapiro et al. affirms the positive role that high levels of physical activity play in improving not only health-related QOL and symptom management (e.g., chronic pain, fatigue, insomnia, sexual dysfunction, metabolic syndrome, bone loss, cognitive dysfunction, and depression), but also return to work in cancer survivors⁵². In addition, increased cardiorespiratory fitness may decrease all-cause mortality among cancer survivors^{53,54}. However, there are currently no effective home-based exercise programs available for improving cardiorespiratory fitness for breast cancer survivors. No studies have precisely investigated cardiorespiratory fitness⁵⁵; however, a small pilot study did estimate VO_2 based on subjective exercise intensity among Japanese breast cancer survivors. Accordingly, the present study seeks to confirm whether our originally developed home-based exercise program (habit-B program) improves VO_{2peak} compared with treatment as usual in sedentary breast cancer survivors in Japan. With the assumption that the program will be widely implemented if successful, it was designed to be (1) home based, (2) quick to implement (only 10 min in total), (3) use only body weight exercises involving the lower limbs, and (4) utilize a wearable device for which personalized ICT support is available. We believe that no similar studies have been implemented.

If it is found that the habit-B program is effective in increasing VO_{2peak} , we will then proceed to the next trial, aiming for its widespread implementation in society. Specifically, the aims of the next study will be (1) to investigate whether

1
2
3
4
5
6 intervention using the program developed in this research but presented in a
7
8 simpler format is effective in establishing exercise habits and (2) to assess whether
9
10 the program can be implemented in societies in Eastern Asia, including in both
11
12 urban and rural Japan and other East Asian countries.
13
14

15
16 We strongly believe that a successful support team comprising specialists in
17
18 the field of exercise science, medicine, rehabilitation, nursing, and patient
19
20 advocacy, as involved in this study, will provide a new horizon in cancer
21
22 survivorship care.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We sincerely thank Dr. Hiroji Iwata, Dr. Hirokazu Arai, Ms. Noriko Watanabe, Dr. Noriaki Tatematsu, Dr. Hikaru Ihira, Mr. Tomoyasu Chigahara, Dr. Taro Ueno, Dr. Shinji Fukuda, and Dr. Eiko Saito for their generous support for the study. We also thank Ms. Ayako Sato for her role as an exercise model.

Contributors KT, EO, RO, YS, TK, and YM conceived the study and drafted the original protocol. KT, EO, RO, YS, TS, AK, TU, TK, and YM participated in refining the protocol. TU developed app and EDC system and managed datacenter. AK played a major role in the statistical analysis. KT, EO, TK, and NS contributed to developing the exercise program. KT, EO and YM drafted the manuscript. All authors participated in, read, and approved the final manuscript.

Funding This study is supported by a National Cancer Center Research and Development Fund (30-A-17).

Competing interests EO has received research support from Nippon Suisan Kaisha, Ltd. YJM has received speaker fees from Pfizer, Mochida, Eli Lilly, Morinaga Milk, and NTT Data and is conducting collaborative research with Morinaga Milk. AK has received speaking fees from Chugai Pharmaceutical Co., Ltd. All other authors declare that they have no competing interests regarding this work.

Ethics approval. The protocol was approved by the Institutional Review Board of the National Cancer Center on 28 February 2019 (ID: 2018-347).

FIGURE LEGENDS

Figure 1. Flow diagram of study participants. HIIT, high-intensity interval training; ICT, information and communication technology.

Figure 2. Study design of the habit-b program (**h**ome-based high-intensity interval training **and** **b**ehavioral modification using **i**nformation and communication **t**echnology on cardiorespiratory fitness and exercise habits for sedentary **b**reast cancer survivors). HIIT, high-intensity interval training; ICT, information and communication technology.

Figure 3. Screenshots of the application for the smartphone-based exercise movie.

Figure 4. Sample of high-intensity interval training using body weight exercise.

Figure 5. Brochure reminding participants about the importance of exercise and providing instructions about physical activity in daily life.

References

1. Denlinger CS, Sanft T, Baker KS, et al. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017;15(9):1140–63. doi: 10.6004/jnccn.2017.0146 [published Online First: 2017/09/07]
2. Public survey about cancer control in Japan. (*the Cabinet Office*), <https://survey.gov-online.go.jp/h26/h26-gantaisaku/5.html> (accessed on 2018/Aug./10)
3. Denlinger CS, Carlson RW, Are M, et al. Survivorship: Introduction and Definition: Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network : JNCCN* 2014;12(1):34–45.
4. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA: A Cancer Journal for Clinicians* 2012;62(4):242–74. doi: 10.3322/caac.21142
5. Hori M MT, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Japanese journal of clinical oncology* 2015;45(9):884–91.
6. Rock CL, Flatt SW, Byers TE, et al. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. *J Clin Oncol* 2015;33(28):3169–76. doi: 10.1200/JCO.2015.61.1095 [published Online First: 2015/08/19]
7. Kuwabara M, Kuwabara R, Niwa K, et al. Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. *Nutrients* 2018;10(8) doi: 10.3390/nu10081011 [published Online First: 2018/08/08]
8. Rogers LQ, Courneya KS, Anton PM, et al. Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled

- 1
2
3
4
5
6 trial. *Breast Cancer Res Treat* 2015;149(1):109–19. doi: 10.1007/s10549-014-
7 3216-z [published Online First: 2014/11/25]
8
- 9 9. Dolan LB, Campbell K, Gelmon K, et al. Interval versus continuous aerobic
10 exercise training in breast cancer survivors—a pilot RCT. *Support Care*
11 *Cancer* 2016;24(1):119–27. doi: 10.1007/s00520-015-2749-y [published
12 Online First: 2015/05/10]
13
14
15
- 16 10. Tanaka H, Desouza CA, Jones PP, et al. Greater rate of decline in maximal
17 aerobic capacity with age in physically active vs. sedentary healthy women.
18 *Journal of applied physiology (Bethesda, Md : 1985)* 1997;83(6):1947–53. doi:
19 10.1152/jappl.1997.83.6.1947 [published Online First: 1998/02/14]
20
21
22
- 23 11. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death
24 in women: the St James Women Take Heart Project. *Circulation*
25 2003;108(13):1554–9. doi: 10.1161/01.Cir.0000091080.57509.E9 [published
26 Online First: 2003/09/17]
27
28
- 29 12. Peel AB, Thomas SM, Dittus K, et al. Cardiorespiratory fitness in breast cancer
30 patients: a call for normative values. *Journal of the American Heart*
31 *Association* 2014;3(1):e000432. doi: 10.1161/jaha.113.000432 [published
32 Online First: 2014/01/15]
33
34
35
- 36 13. Tabata I, Nishimura K, Kouzaki M, et al. Effects of moderate-intensity endurance
37 and high-intensity intermittent training on anaerobic capacity and VO2max.
38 *Med Sci Sports Exerc* 1996;28(10):1327–30. [published Online First:
39 1996/10/01]
40
41
42
- 43 14. Batacan RB, Jr., Duncan MJ, Dalbo VJ, et al. Effects of high-intensity interval
44 training on cardiometabolic health: a systematic review and meta-analysis of
45 intervention studies. *British journal of sports medicine* 2017;51(6):494–503.
46 doi: 10.1136/bjsports-2015-095841 [published Online First: 2016/11/01]
47
48
- 49 15. Mallol M, Bentley DJ, Norton L, et al. Comparison of Reduced-Volume High-
50 Intensity Interval Training and High-Volume Training on Endurance
51 Performance in Triathletes. *International journal of sports physiology and*
52 *performance* 2019;14(2):239–45. doi: 10.1123/ijsp.2018-0359 [published
53 Online First: 2018/08/07]
54
55
56
57
58
59
60


16. Mugele H, Freitag N, Wilhelmi J, et al. High-intensity interval training in the therapy and aftercare of cancer patients: a systematic review with meta-analysis. *J Cancer Surviv* 2019 doi: 10.1007/s11764-019-00743-3 [published Online First: 2019/02/27]
17. McRae G, Payne A, Zelt JG, et al. Extremely low volume, whole-body aerobic-resistance training improves aerobic fitness and muscular endurance in females. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme* 2012;37(6):1124-31. doi: 10.1139/h2012-093 [published Online First: 2012/09/22]
18. Gresham G, Hendifar AE, Spiegel B, et al. Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. *npj Digital Medicine* 2018;1(1):27. doi: 10.1038/s41746-018-0032-6
19. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans Physical Activity Guidelines for Americans Physical Activity Guidelines for Americans. *JAMA* 2018;320(19):2020-28. doi: 10.1001/jama.2018.14854
20. Akechi T, Yamaguchi T, Uchida M, et al. Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial. *BMJ Open* 2018;8(11):e024794. doi: 10.1136/bmjopen-2018-024794 [published Online First: 2018/11/11]
21. Gresham G, Schrack J, Gresham LM, et al. Wearable activity monitors in oncology trials: Current use of an emerging technology. *Contemp Clin Trials* 2018;64:13-21. doi: 10.1016/j.cct.2017.11.002 [published Online First: 2017/11/14]
22. Ministry of Health, Labour and Welfare Summary of results of the national nutrition survey, Japan. 2017.;<https://www.mhlw.go.jp/toukei/itiran/gaiyo/k-eisei.html> (accessed on 2018/Aug./10 (in Japanese))
23. Bandura A. Health promotion by social cognitive means. *Health education & behavior : the official publication of the Society for Public Health Education*

- 2004;31(2):143–64. doi: 10.1177/1090198104263660 [published Online First: 2004/04/20]
24. Stacey FG, James EL, Chapman K, et al. A systematic review and meta-analysis of social cognitive theory-based physical activity and/or nutrition behavior change interventions for cancer survivors. *J Cancer Surviv* 2015;9(2):305–38. doi: 10.1007/s11764-014-0413-z [published Online First: 2014/11/30]
25. Abedtash H, Holden RJ. Systematic review of the effectiveness of health-related behavioral interventions using portable activity sensing devices (PASDs). *Journal of the American Medical Informatics Association : JAMIA* 2017;24(5):1002–13. doi: 10.1093/jamia/ocx006 [published Online First: 2017/03/25]
26. Taylor HL, Buskirk E, Henschel A. Maximal oxygen intake as an objective measure of cardio-respiratory performance. *Journal of applied physiology* 1955;8(1):73–80. doi: 10.1152/jappl.1955.8.1.73 [published Online First: 1955/07/01]
27. Whipp BJ, Davis JA, Torres F, et al. A test to determine parameters of aerobic function during exercise. *Journal of applied physiology: respiratory, environmental and exercise physiology* 1981;50(1):217–21. doi: 10.1152/jappl.1981.50.1.217 [published Online First: 1981/01/01]
28. Ross RM, Murthy JN, Wollak ID, et al. The six minute walk test accurately estimates mean peak oxygen uptake. *BMC pulmonary medicine* 2010;10:31. doi: 10.1186/1471-2466-10-31 [published Online First: 2010/05/28]
29. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc* 2014;15(2):95–101. doi: 10.1016/j.jamda.2013.11.025 [published Online First: 2014/01/28]
30. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. *The New England journal of medicine* 2009;361(7):664–73. doi: 10.1056/NEJMoa0810118 [published Online First: 2009/08/14]
31. Neil-Sztramko SE, Kirkham AA, Hung SH, et al. Aerobic capacity and upper limb strength are reduced in women diagnosed with breast cancer: a systematic


- 1
2
3
4
5
6 review. *Journal of physiotherapy* 2014;60(4):189–200. doi:
7 10.1016/j.jphys.2014.09.005 [published Online First: 2014/12/03]
8
- 9 32. Van der Weijden–Van Doornik EM, Slot DE, Burtin C, et al. Grip Strength in
10 Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine
11 Therapy: Systematic Review. *Phys Ther* 2017;97(9):904–14. doi:
12 10.1093/ptj/pzx069 [published Online First: 2017/10/04]
13
- 14 33. Herrero F, San Juan AF, Fleck SJ, et al. Combined aerobic and resistance
15 training in breast cancer survivors: A randomized, controlled pilot trial.
16 *International journal of sports medicine* 2006;27(7):573–80. doi: 10.1055/s-
17 2005–865848 [published Online First: 2006/06/28]
18
- 19 34. Foley MP, Hasson SM. Effects of a Community–Based Multimodal Exercise
20 Program on Health–Related Physical Fitness and Physical Function in Breast
21 Cancer Survivors:A Pilot Study. *Integrative Cancer Therapies*
22 2016;15(4):446–54. doi: 10.1177/1534735416639716
23
- 24 35. Maruya K, Fujita H, Arai T, et al. Identifying elderly people at risk for cognitive
25 decline by using the 2–step test. *J Phys Ther Sci* 2018;30(1):145–49. doi:
26 10.1589/jpts.30.145
27
- 28 36. Organization WH. Global Physical Activity Surveillance [Available from:
29 <http://www.who.int/ncds/surveillance/steps/GPAQ/en/> accessed Aug. 10
30 2018.
31
- 32 37. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity
33 questionnaire (GPAQ) in assessing levels and change in moderate–vigorous
34 physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255.
35 doi: 10.1186/1471–2458–14–1255 [published Online First: 2014/12/11]
36
- 37 38. Chu AH, Ng SH, Koh D, et al. Reliability and Validity of the Self– and Interviewer–
38 Administered Versions of the Global Physical Activity Questionnaire (GPAQ).
39 *PLoS One* 2015;10(9):e0136944. doi: 10.1371/journal.pone.0136944 [published
40 Online First: 2015/09/04]
41
- 42 39. Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ):
43 nine country reliability and validity study. *Journal of physical activity & health*
44 2009;6(6):790–804. [published Online First: 2010/01/28]
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 40. Vickberg SM. The Concerns About Recurrence Scale (CARS): a systematic
7 measure of women's fears about the possibility of breast cancer recurrence.
8 *Ann Behav Med* 2003;25(1):16–24.
9
- 10 41. Momino K, Akechi T, Yamashita T, et al. Psychometric Properties of the
11 Japanese Version of the Concerns About Recurrence Scale (CARS–J).
12 *Japanese Journal of Clinical Oncology* 2014;44(5):456–62. doi:
13 10.1093/jjco/hyu032
14
- 15 42. Muramatsu K, Miyaoka H, Kamijima K, et al. The patient health questionnaire,
16 Japanese version: validity according to the mini–international
17 neuropsychiatric interview–plus. *Psychological reports* 2007;101(3 Pt 1):952–
18 60. doi: 10.2466/pr0.101.3.952–960 [published Online First: 2008/02/01]
19
- 20 43. Okajima I, Nakajima S, Kobayashi M, et al. Development and validation of the
21 Japanese version of the Athens Insomnia Scale. *Psychiatry and clinical
22 neurosciences* 2013;67(6):420–25. doi: 10.1111/pcn.12073 [published Online
23 First: 2013/08/05]
24
- 25 44. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation
26 of an instrument based on ICD–10 criteria. *Journal of psychosomatic
27 research* 2000;48(6):555–60.
28
- 29 45. Rabin R, de Charro F. EQ–5D: a measure of health status from the EuroQol
30 Group. *Annals of medicine* 2001;33(5):337–43. [published Online First:
31 2001/08/09]
32
- 33 46. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ–5D population value set:
34 the case of Japan. *Health economics* 2002;11(4):341–53. doi: 10.1002/hec.673
35 [published Online First: 2002/05/15]
36
- 37 47. Monda V, Villano I, Messina A, et al. Exercise Modifies the Gut Microbiota with
38 Positive Health Effects. *Oxidative medicine and cellular longevity*
39 2017;2017:3831972. doi: 10.1155/2017/3831972 [published Online First:
40 2017/03/31]
41
- 42 48. Zebrowska A, Mizia–Stec K, Mizia M, et al. Omega–3 fatty acids supplementation
43 improves endothelial function and maximal oxygen uptake in endurance–
44 trained athletes. *European journal of sport science* 2015;15(4):305–14. doi:
45 10.1080/17461391.2014.949310 [published Online First: 2014/09/02]
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 49. Liu G, Muhlhausler BS, Gibson RA. A method for long term stabilisation of long
7 chain polyunsaturated fatty acids in dried blood spots and its clinical
8 application. *Prostaglandins, leukotrienes, and essential fatty acids*
9 2014;91(6):251–60. doi: 10.1016/j.plefa.2014.09.009 [published Online First:
10 2014/12/03]
11
12
13
14 50. Scribbans TD, Vecsey S, Hankinson PB, et al. The Effect of Training Intensity on
15 VO2max in Young Healthy Adults: A Meta-Regression and Meta-Analysis.
16 *International journal of exercise science* 2016;9(2):230–47. [published Online
17 First: 2016/05/18]
18
19
20 51. Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise
21 training in postmenopausal breast cancer survivors: cardiopulmonary and
22 quality of life outcomes. *J Clin Oncol* 2003;21(9):1660–8. doi:
23 10.1200/jco.2003.04.093 [published Online First: 2003/05/02]
24
25
26 52. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. *The*
27 *New England journal of medicine* 2001;344(26):1997–2008. doi:
28 10.1056/nejm200106283442607 [published Online First: 2001/06/30]
29
30
31 53. Peel JB, Sui X, Adams SA, et al. A prospective study of cardiorespiratory fitness
32 and breast cancer mortality. *Med Sci Sports Exerc* 2009;41(4):742–8. doi:
33 10.1249/MSS.0b013e31818edac7 [published Online First: 2009/03/12]
34
35
36 54. Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-
37 related decline across the breast cancer survivorship continuum. *J Clin*
38 *Oncol* 2012;30(20):2530–7. doi: 10.1200/JCO.2011.39.9014 [published Online
39 First: 2012/05/23]
40
41
42 55. Okumatsu K, Tsujimoto T, Wakaba K, et al. Physical fitness level in Japanese
43 breast cancer survivors. *Japanese Journal of Physical Fitness and Sports*
44 *Medicine* 2018;67(2):169–76. doi: 10.7600/jspfsm.67.169
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



3 min and 10 sec Warm up	Squat	rest	Lunge	rest	Squat	rest	Lunge	rest	Squat	rest	Lunge	rest	Squat	rest	Lunge	3 min cool down
	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	

10 min

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



NCC 法政大学
habit-B

1人ではなくみんなで頑張りましょう!

【TSUKIJI habit-B プロジェクト】
現在、私たちは乳がんサバイバー向けに有酸素能力を向上させるための運動プログラムを開発しています。

〒104-0045 東京都中央区豊町5-1-1
https://www.ncc.go.jp/cj/cp/ab/d/online/habit_b_support/project/20181228175920.html
お問い合わせ habit-Bプロジェクト
国立がん研究センター 健康室 / 法政大学 健康実習



Let's training

乳がんサバイバーのあなたへ

体力向上のためのトレーニング

自宅で継続・安心トレーニングのご紹介



こんなことありませんか？

<input type="checkbox"/> 体力の低下を感じている	<input type="checkbox"/> 旧もとの体力に戻したい
<input type="checkbox"/> 疲れやすく感じる	<input type="checkbox"/> 一人でトレーニングは不安だ
<input type="checkbox"/> そろそろ運動をはじめてみたい	<input type="checkbox"/> 毎日を楽しんで過ごしたい

毎日の生活に運動を取り入れましょう!

疲れにくいカラダをつくる4つの運動

心臓機能を高く維持することは疲れにくいカラダをつくり、乳がんサバイバーにとってきわめて重要です。下記の運動は、ふともやおしりの筋肉を意識しながら丁寧に実施することで運動中に心拍数を上昇させて心臓機能を向上させます。さらにこれらの運動は認識やサルコペニアの予防にも役立ちます。

Step 1



Point
膝つま先の向きを揃えましょう

Step 2



Point
膝つま先の向きを揃えて、両足のつま先を揃えましょう

Step 3



Point
膝を深く落としましょう

Step 4



Point
しゃがみ込むとき、膝立ての姿勢から立ち上がり、膝を一歩スライドの姿勢を繰り返しましょう。

運動強度 ★	運動強度 ★★	運動強度 ★★★	運動強度 ★★★★★
<p>スクワット</p> <p>足を肩幅からやや広めに広げ、お尻を後ろに突き出しながら、上体を倒し過ぎないように膝の曲げ伸ばしを行います。</p>	<p>フロントランジ</p> <p>片足づつ足を前に出しましょう。背筋を伸ばして、前に出した足の膝がつま先より前に出ないように膝を曲げましょう。</p>	<p>ステイパーズランジ</p> <p>左右のジャンプ動作が含まれます。膝へ負担がかかる姿勢を避けるように注意しましょう。背筋の曲も、膝つま先の向きを揃えて、次の動作へスムーズにつなげられるようにしましょう。</p>	<p>バーピー</p> <p>全身を効率よく動かす運動です。</p> <ol style="list-style-type: none"> ①しゃがみこんで手をつく ②手をついたまま飛び跳ねて足を後ろに伸ばして、膝が足先の姿勢になる ③飛び跳ねて膝を曲げて、しゃがみこんだ姿勢にもどる ④立ち上がる



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym (p1)
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry (p4, 20)
	2b	All items from the World Health Organization Trial Registration Data Set (n/a)
Protocol version	3	Date and version identifier (p4, 20)
Funding	4	Sources and types of financial, material, and other support (p23)
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors (p23)
	5b	Name and contact information for the trial sponsor (p23)
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities (n/a)
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) (n/a)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention (p6)
	6b	Explanation for choice of comparators (p11)
Objectives	7	Specific objectives or hypotheses (p6)
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) (p8)

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained(p5)
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) (p8,9)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered(p9-11)
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) (p13)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) (p11)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial(p12,13)
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended(p14-18)
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure 1,2, and Table 1)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations(p19)
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size(n/a)

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions(p8,12)
---------------------	-----	---

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned(p8,12)
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions(p8,12)
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how(p12)
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial(n/a)
17			
18			
19			

Methods: Data collection, management, and analysis

21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
22	methods		trial data, including any related processes to promote data quality (eg,
23			duplicate measurements, training of assessors) and a description of
24			study instruments (eg, questionnaires, laboratory tests) along with
25			their reliability and validity, if known. Reference to where data
26			collection forms can be found, if not in the protocol(p18)
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols(p10,13)
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol(p11,12)
36			
37			
38			
39			
40	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
41	methods		Reference to where other details of the statistical analysis plan can be
42			found, if not in the protocol(p18,19)
43			
44		20b	Methods for any additional analyses (eg, subgroup and adjusted
45			analyses) (p18,19)
46			
47		20c	Definition of analysis population relating to protocol non-adherence
48			(eg, as randomised analysis), and any statistical methods to handle
49			missing data (eg, multiple imputation) (p18,19)
50			
51			

Methods: Monitoring

52			
53			
54	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
55			and reporting structure; statement of whether it is independent from
56			the sponsor and competing interests; and reference to where further
57			details about its charter can be found, if not in the protocol.
58			Alternatively, an explanation of why a DMC is not needed(p11,12)
59			
60			

1		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial(n/a)
2			
3			
4			
5			
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct(p17)
7			
8			
9			
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor(p11,12)
11			
12			
13			
14			

Ethics and dissemination

15			
16			
17	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval(p4)
18			
19			
20			
21	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) (n/a)
22			
23			
24			
25			
26	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) (n/a)
27			
28			
29		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable(n/a)
30			
31			
32			
33	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial(p12)
34			
35			
36			
37	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site(p23)
38			
39			
40	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators(n/a)
41			
42			
43			
44			
45	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation(p17,18)
46			
47			
48	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions(p4,20)
49			
50			
51			
52			
53			
54			
55		31b	Authorship eligibility guidelines and any intended use of professional writers(p11)
56			
57			
58		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code(n/a)
59			
60			

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates (n/a)
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable (p17)

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

BMJ Open

Effect of home-based high-intensity interval training and behavioral modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: the habit-B study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030911.R2
Article Type:	Protocol
Date Submitted by the Author:	16-Jul-2019
Complete List of Authors:	Tsuji, Katsunori; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Ochi, Eisuke; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences; Hosei University, Faculty of Bioscience and Applied Chemistry Okubo, Ryo; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Shimizu, Yoichi; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences Kuchiba, Aya; National Cancer Center Japan, Division of Biostatistical Research, Center for Public Health Sciences; National Cancer Center Japan, Biostatistics Division, Center for Research Administration and Support Ueno, Taro; SUSMED, Inc. Shimazu, Taichi; National Cancer Center Japan, Division of Prevention, Center for Public Health Sciences Kinoshita, Takayuki; National Cancer Center Hospital, Department of Breast Surgery Sakurai, Naomi; Cancer Solutions Matsuoka, Yutaka; National Cancer Center Japan, Division of Health Care Research, Center for Public Health Sciences
Primary Subject Heading:	Sports and exercise medicine
Secondary Subject Heading:	Mental health, Oncology
Keywords:	Breast tumours < ONCOLOGY, SPORTS MEDICINE, PREVENTIVE MEDICINE, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open *Study protocols*

Effect of home-based high-intensity interval training and behavioral modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: the habit-B study protocol for a randomized controlled trial

Katsunori Tsuji^{1*}, Eisuke Ochi^{1, 2*}, Ryo Okubo¹, Yoichi Shimizu¹, Aya Kuchiba^{3,4}, Taro Ueno⁵, Taichi Shimazu⁶, Takayuki Kinoshita⁷, Naomi Sakurai⁸, Yutaka J. Matsuoka¹

1. Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
2. Faculty of Bioscience and Applied Chemistry, Hosei University, Tokyo, Japan
3. Division of Biostatistical Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
4. Biostatistics Division, Center for Research Administration and Support, National Cancer Center Japan, Tokyo, Japan
5. SUSMED, Inc., Tokyo, Japan
6. Division of Prevention, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
7. Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan
8. Cancer Solutions, Tokyo, Japan

* These two authors contributed equally to this work

Corresponding author

Yutaka J. Matsuoka, MD, PhD

Division of Health Care Research, Center for Public Health Sciences, National

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cancer Center Japan, Tokyo, Japan

E-mail address: yumatsuo@ncc.go.jp, Phone: +81-3-3547-5201 ext. 3382

For peer review only

ABSTRACT

Introduction

Maintaining high levels of physical activity not only helps to maintain and improve physical health and quality of life, but also plays a role in reducing adverse effects due to cancer treatments. Moreover, a greater degree of cardiorespiratory fitness is associated with reduced risk of all-cause mortality. However, there are no home-based programs for improving cardiorespiratory fitness using body weight exercises for breast cancer survivors. This study will assess the efficacy of the newly developed habit-B program on maximum oxygen uptake compared with treatment as usual with wearable device. The effects of this program on exercise habits, level of physical activity, physical fitness, and subjective indices will also be investigated.

Methods and analysis

This is a 12-week, parallel-group, single blind, randomized controlled trial. Allocation will be managed by a central server using a computer-generated random allocation sequence provided by an independent data center. Participants will be assigned to the habit-B Program (high-intensity interval training exercise, exercise counseling + guidance, home-based exercise support using information and communication technology, and a wearable device) or treatment as usual with a wearable device. Subjects will be sedentary women aged 20 to 59 years who have received breast surgery in the past 2 to 13 months after diagnosis of invasive breast cancer (Stage I-IIa) and have never received chemo-therapy except for

1
2
3
4
5
6 hormone therapy. The primary endpoint is the change in peak oxygen uptake
7
8 (VO_{2peak} ; mL/kg/min) between the groups after 12 weeks of intervention.
9

10 **Ethics and dissemination**

11
12
13 The study protocol was approved by the Institutional Review Board of the National
14
15
16 Cancer Center Japan on 28 February 2019 (ID: 2018-347). The findings will be
17
18
19 disseminated through peer reviewed publications and conference presentations.
20

21
22
23 **Trial status** Study enrolment, intervention, and data collection are ongoing. The
24
25
26 estimated end date for this study is on March 31, 2021.
27

28
29 **Trial registration number** UMIN000036400; Pre-results.
30

31 **Strengths and limitations of this study**

- 32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
1. This clinical trial will be the world's first home-based HIIT program using ICT to increase cardiorespiratory fitness in sedentary breast cancer survivors.
 2. The habit-B program is designed based on the theory of Bandura for sedentary breast cancer survivors to develop exercise habits.
 3. Collaborative work with professionals in the field of clinical oncology, exercise science, mental health, rehabilitation, public health, nursing, and cancer survivors constitutes a new model for cancer survivorship care.
 4. We cannot rigorously exclude breast cancer survivors who may have exercise habits because the definition of sedentary subjects will be based on self-report.

58 **INTRODUCTION**

1
2
3
4
5
6 Breast cancer, which is one of the most common cancers affecting women,
7
8 newly affects over 86,000 women each year¹. It is recommended that cancer
9
10 survivors acquire and maintain healthy behaviors to extend survival, such as
11
12 staying reasonably fit through appropriate physical exercise and having a healthy
13
14 diet ². High levels of physical activity not only help to maintain and improve
15
16 physical health and quality of life (QOL), but also play a role in reducing short- and
17
18 long-term side effects of cancer treatment. The American Cancer Society guidelines
19
20 recommend a minimum of 150 min moderate physical activity or 75 min intensive
21
22 physical activity per week, in addition to usual physical activity in daily life³, and
23
24 the Japan Breast Cancer Society's Clinical Guidelines for Breast Cancer strongly
25
26 recommend maintaining a high level of physical activity^{4 5}.

27
28
29
30
31
32
33 The ENERGY Trial, an early and representative study conducted in the US,
34
35 demonstrated the effectiveness of a home exercise program and nutritional advice
36
37 to promote weight loss among breast cancer survivors⁶. However, because the
38
39 proportion of overweight adults in Japan is lower than that in the US⁷, it is not
40
41 appropriate to adopt the US-developed program in Japan. It would appear suitable
42
43 though to develop intervention around measurements of VO_{2peak} , the globally
44
45 important health indicator of cardiorespiratory fitness ^{8 9}.

46
47
48
49
50
51 VO_{2peak} decreases with age, and a meta-analysis has suggested that women
52
53 who are sedentary have a decrease of 3.2 mL/kg/min over 10 years¹⁰. A cohort
54
55 study suggested that the all-cause mortality rate decreased by 17% for each 1
56
57 metabolic equivalent (MET) increase (3.5 mL/kg/min) in VO_{2peak} for women¹¹. A
58
59
60

1
2
3
4
5
6 systematic review demonstrated that the median VO_{2peak} of breast cancer
7
8 survivors not receiving chemotherapy was lower than that of healthy sedentary
9
10 women (25.3 mL/kg/min vs. 29.7 mL/kg/min)¹². In a 16-year follow-up study of
11
12 breast cancer survivors¹², hazard ratios were 0.67 for the moderate VO_{2peak} group
13
14 (8.5 METs) and 0.45 for the high group (11.1 METs) compared with the low VO_{2peak}
15
16 group (6.7 METs). In this report, the mortality rate was reduced by maintaining a
17
18 VO_{2peak} of 8 METs or above¹². Against this background, it is necessary to develop an
19
20 exercise program that will increase VO_{2peak} in breast cancer survivors.
21
22
23
24
25

26 When considering how to increase VO_{2peak} , research has advanced in recent
27
28 years with the use of HIIT for athletes and sedentary populations¹³⁻¹⁵. HIIT allows
29
30 subjects to exercise at vigorous intensity within 10 min, resulting in improved
31
32 cardiorespiratory fitness^{9 16}. A recent systematic review showed, based on the
33
34 findings of 12 studies of HIIT conducted in supervised experimental settings, that
35
36 HIIT appeared to be more beneficial than treatment as usual for improving
37
38 physical fitness and health-related outcomes in cancer survivors during any stage
39
40 of treatment and aftercare¹⁶. To our knowledge, only one study has evaluated
41
42 changes in cardiorespiratory fitness following a home-based HIIT program, which
43
44 involved healthy young women¹⁷. Given that no home-based HIIT programs with
45
46 body weight exercises have been reported for breast cancer survivors to date, it is
47
48 necessary to develop such programs and examine their efficacy and feasibility.
49
50
51
52
53
54

55 Recent emerging technologies such as smartphone applications (apps) and
56
57 wearable devices are promising tools for the monitoring of cancer patients' daily
58
59
60

1
2
3
4
5
6 activity levels and for facilitating coaching, self-monitoring, feedback, and
7
8 encouragement to exercise^{18,19}. Apps²⁰ and wearable devices²¹ are being used for
9
10 both subjective and objective measures in the field of clinical oncology. However,
11
12 further investigations are needed of their potential utility in objective evaluations
13
14 of physical activity as well as in lifestyle modification and maintenance and
15
16 enhancement of QOL in real-world settings.
17
18
19

20
21 The aim of this study is to investigate the effect of the newly developed
22
23 habit-B program, comprising **h**ome-based high-intensity interval training **a**nd
24
25 **b**ehavioral modification using **i**nformation and communication **t**echnology on
26
27 cardiorespiratory fitness and exercise habits for sedentary **b**reast cancer
28
29 survivors. We will investigate whether the habit-B program improves VO_{2peak}
30
31 compared with a control group as well as investigate the safety and feasibility of
32
33 program. The secondary objectives are to investigate the effect of this program on
34
35 exercise habits, physical activity level, physical function, and subjective measures.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

Trial design

In this study 12-week, parallel-group, single blind, randomized controlled trial (Figure 1), participants will be randomly assigned to intervention either with the habit-B program (HIIT exercise, exercise counseling + guidance, home-based exercise support using ICT, and a wearable device) or treatment as usual with a wearable device (Fitbit Versa smart watch; Fitbit Inc., San Francisco, CA). An independent data center will provide computer-generated random allocation. Participants will be assigned by the minimization method, a form of dynamic randomization, using two prognostic factors: VO_{2peak} and age. Based on the allocation sequences, the contents of the app that participants use during the trial will be assigned automatically to either the habit-B program or control.

Participants

The eligibility criteria for participants are as follows: (1) female, aged between 20 and 59 years at diagnosis (stages I-IIa); (2) diagnosed with invasive breast cancer within 2 to 13 months after surgery; (3) not requiring cancer chemotherapy aside from hormone therapy; (4) currently engages in not more than moderate intensity exercise for 30 min on 2 separate days per week (total of 60 min), which is based on the National Health and Nutrition Survey Japan²²; (5) ability to complete an electronic patient reported outcome (e-PRO) questionnaire via a smartphone; (6) consent to trial participation obtained in writing from the

1
2
3
4
5
6 patient themselves; and (7) ability to read, write, and understand Japanese. The
7
8 exclusion criteria are as follows: (1) judged to have severely reduced cognitive
9
10 function by a primary physician; (2) exercise judged to be risky by a primary
11
12 physician; (3) history of smoking within the previous 12 months; (4) body mass
13
14 index of 30 or above; (5) abnormal electrocardiogram in preoperative testing,
15
16 resting heart rate (HR) below 50 beats/min or above 100 beats/min, or stage III
17
18 hypertension or above (diastolic blood pressure over 110 mmHg or systolic blood
19
20 pressure over 180 mmHg); and (6) judged unfit for the trial by a primary physician
21
22 for other reasons such as the administration of beta-adrenergic blocking agents.
23
24
25
26
27
28
29
30

31 **Interventions**

32
33 This will be a randomized, single-blind study. Participants will be
34
35 enrolled and assigned using an electronic data capture system with an app. The
36
37 protocol intervention will be started within 21 days of enrollment. If for some
38
39 reason the start is delayed beyond 21 days, the reason will be entered into the
40
41 electronic Case Report Form (eCRF). If it is determined that the intervention
42
43 cannot be started, the details will be noted in the eCRF as “protocol intervention
44
45 stopped.”
46
47
48
49
50
51

52 53 The habit-B program group

54
55 The habit-B program (Figure 2) comprises home-based exercise support
56
57 utilizing 6 weeks of exercise counseling/exercise guidance (once per week, 6 times
58
59
60

1
2
3
4
5
6 total, 30 min per session) and 12 weeks of ICT interventions, which are provided
7
8 with personalized e-mail (once per week, 12 times in total), and a newly developed
9
10 exercise app (during each exercise session, shown in Figure 3). Participants will be
11
12 encouraged to complete the following program HIIT using specific body weight
13
14 exercises for one 10-min training session 3 times a week for 12 weeks (total of 36
15
16 sessions during the trial period, as shown in Figures 2 and 4): (1) one bout of 10-
17
18 min exercises; (2) a total of 10 min exercise, comprising a 3-min warm-up, 4-min
19
20 training (8 sets of 20 s exercise + 10 s rest), and a 3-min cool-down; (3) these
21
22 training exercises are designed to increase in intensity each week; and (4) the
23
24 details of these exercises are divided into three stages according to
25
26 cardiorespiratory fitness (VO_{2peak}) at Week 0 and the contents of training are
27
28 designed to increase physical strength incrementally in accordance with the
29
30 individual's level of strength. In addition, we will continue to follow up on the
31
32 between-group differences in e-PRO data of change from baseline to 24 and 36
33
34 weeks post-intervention.
35
36
37
38
39
40
41
42
43

44 The social cognitive theory proposed by Bandura et al. may be helpful to
45
46 apply when considering interventions for behavioral change²³, chiefly in that it
47
48 affords a framework for understanding the underlying reasons for making and
49
50 maintaining health behaviors²⁴. Its key concepts involve (1) understanding of health
51
52 risks and benefits, (2) perceived self-efficacy of being able to control one's own
53
54 health habits, (3) projected costs and benefits or expected outcomes, (4) specified
55
56 health goals with short- and long-term intentions to engage in the behavior, (5)
57
58
59
60

1
2
3
4
5
6 perceived facilitators and social support, and (6) barriers to instituting change^{23 24}.

7
8 In the present study, we developed the exercise program applying the first 5
9
10 concepts.

11
12
13 We will also provide the participant a brochure as a reminder to exercise and
14
15 will check the type of physical activity they engage in in daily life (Figure 5). When
16
17 developing the habit-B program, we collaborated closely with exercise scientists,
18
19 oncologists, physical therapists, nurses, mental health practitioners, and breast
20
21 cancer survivors.
22
23
24
25
26
27

28 29 Control group

30
31 The control group will be provided a wearable device and setup support
32
33 at the start of intervention. Self-monitoring using the wearable device will be
34
35 recommended during the trial period. While there are no reports of increasing
36
37 VO_{2peak} with the use of a wearable device alone, other reports have ruled out their
38
39 efficacy with regard to effects on exercise habits²⁵. In this study, the wearable
40
41 devices are used only to monitor physical activity in the control group.
42
43
44
45
46
47

48 49 **PROCEDURE**

50 51 **Data collection, management, monitoring, and auditing**

52
53 We will collect all data except qualitative interview data, blood samples,
54
55 fecal samples, and medical economic costs through the e-PRO system. Those who
56
57 provide consent will be enrolled in the app-based e-PRO system on their
58
59
60

1
2
3
4
5
6 smartphone. If the entered data is insufficient, enrollment will not be accepted
7
8 until all fields are completed at baseline. The electronic data capture system will be
9
10 used for data management and central monitoring. Because this exercise program
11
12 will not be invasive, there is no need to establish a data monitoring committee or
13
14 to complete auditing in this study.
15
16
17
18
19
20

21 **Random assignment and assignment adjustment factors**

22
23 After enrollment and the additional input of the VO_{2peak} value, patients
24
25 will be randomly assigned. In the process of random assignment, VO_{2peak} (obtained
26
27 from the baseline measurement performed after obtaining informed consent) and
28
29 age will be used as assignment adjustment factors, and automatic assignment will
30
31 be performed using the data center's assignment feature. Only the measurer will
32
33 be blinded in this study, because interventions differ for the intervention group
34
35 and control group.
36
37
38
39
40
41
42
43

44 **Dataset availability**

45
46 The data sharing policy in this study is defined with reference to the
47
48 example proposed by the International Committee of Medical Journal Editors
49
50 (ICMJE): Individual participant data will be made publicly available for a 5-year
51
52 period through the University Hospital Medical Information Network – Individual
53
54 Case Data Repository (UMIN-ICDR) (<https://www.umin.ac.jp/icdr/index-j.html>).
55
56
57
58
59
60

Concomitant treatments

There are no regulated concomitant therapies or supportive therapies in this study.

Stopping rules for participants

Situations in which the intervention protocol is terminated for any of the following reasons will be defined as stopping of the protocol intervention: (1) dropping out due to withdrawal of consent or inability to measure the primary endpoint (VO_{2peak}); (2) if a primary physician deems it necessary to stop the protocol intervention for a participant due to adverse events such as stress; (3) death of the patient during the protocol intervention period; (4) sudden worsening of the participant's condition after enrollment or discovery of a protocol violation or ineligibility. A researcher will report the reason for stopping the protocol intervention to the data center. In this event, as long as consent is not withdrawn, follow-up including the questionnaire survey will be continued.

Stopping of the assessment

Situations in which the participant declines assessment will effectively stop the assessment. A researcher will confirm the possibility of implementing the remaining parts of the intervention and follow-up with the participant. Stopping of the assessment will be recorded along with the details of the reason for stopping.

1
2
3
4
5
6 As a rule, the remaining aspect of follow-up will be implemented as stipulated per
7
8 protocol.
9

10 11 12 13 **Assessment measures**

14
15
16 Table 1 shows the outcome measurement schedule.
17

18
19
20
21 **Primary outcome measure: Cardiorespiratory fitness (VO_{2peak})**

22
23 VO_{2peak} is the maximum oxygen uptake observed during exercise
24 tolerance testing and is used as an indicator of cardiorespiratory fitness^{26 27}. For
25 each participant, VO_{2peak} will be measured using the incremental multistage load
26 method with a bicycle ergometer (Ergomedic 828E, Monark, Stockholm, Sweden)
27 at 60 revolutions per min (rpm). The test will begin at 0.5 kp and increase by 0.25
28 kp per min until exhaustion. When the participant's pedal rotation speed drops
29 below 55 rpm 3 times, the test will be deemed concluded. Respiratory gases will be
30 analyzed using an automatic gas analyzer (Air Monitor AE-310S, Minato Medical
31 Science Co., Ltd., Osaka, Japan). Rated perceived exertion and HR will be recorded
32 after 45 s in each stage. The maximum value of VO_2 observed during exercise will
33 be used as the VO_{2peak} .
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Secondary outcome measures**

55
56 *Physical function*
57
58
59
60

1
2
3
4
5
6 An alternative indicator of VO_{2peak} the 6-min walk test (m), will be
7
8 performed²⁸. Walking speed (m/s), a diagnostic criterion for sarcopenia, will also
9
10 be measured. A 5-m section in the middle of an 11-m line will be measured to
11
12 calculate walking speed²⁹. One-repetition maximum for leg press, which reflects
13
14 muscle strength in the lower body, will be assessed using a leg press machine
15
16 (Powertec Leg Press P-LP16; Powertec, Paramount, CA)^{30 31}. After a thorough
17
18 warm-up, measurements will be performed by incrementally increasing the load
19
20 until a weight, which can be lifted only once, is reached. Load will be increased by
21
22 two levels at a time. Grip strength (TKK 5401 Grip-D; Takei, Niigata, Japan) will
23
24 also be measured^{31 32}. The chair stand test, which reflects combined leg strength
25
26 for the lower limbs as a whole, will be performed^{31 33}. Participants will sit and
27
28 stand from a chair for 10 s and the number of chair stands will be measured. The
29
30 timed up and go test, which is used in clinical settings as an assessment of
31
32 functionality as well as muscular strength, will also be performed³¹. The functional
33
34 reach test, which as a method of assessing dynamic balance is considered an
35
36 indicator of expected fall risk, will also be performed³⁴. While keeping the hand at
37
38 the same height, the participant will extend their arm forward as far as possible,
39
40 without moving the feet, to make a mark at the farthest point they can reach.
41
42 Lifting the heels and standing on tiptoe is allowed. The two-step test will also be
43
44 performed³⁵. This test comprehensively assesses ability to walk, including leg
45
46 strength, balance, and flexibility. Based on bioelectrical impedance analysis, a body
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 composition meter (MC-780A-N, TANITA, Japan) will be used to send a weak
7
8 electrical current through the body via electrodes.
9

10 11 12 13 *Physical activity level*

14
15
16 The Global Physical Activity Questionnaire (GPAQ) was developed in
17
18 2002 as an internationally standardized questionnaire for surveying physical
19
20 activity level. The GPAQ is widely used in policy development by the World Health
21
22 Organization³⁶⁻³⁸. The face validity of the Japanese version has been confirmed³⁹.
23
24 In addition, as an objective measure of physical activity during the research period,
25
26 resting HR, steps, distance, calorie expenditure, and the duration of each sleep
27
28 stage as well as wake up time will be measured using an activity monitor and
29
30 logged for 24-h periods (Fitbit versa, Fitbit Inc., San Francisco, CA). Maximum HR
31
32 during exercise will also be measured to confirm whether the intensity of the
33
34 exercise being implemented is appropriate. The accurately measured group will be
35
36 defined as the group who wears the Fitbit versa at least 60% of the time during the
37
38 12-week intervention period.
39
40
41
42
43
44
45
46
47
48

49 *Subjective measures*

50
51 Fear of cancer recurrence (FCR) will be assessed by the overall fear index
52
53 score on the Concerns About Recurrence Scale^{40 41}. This instrument comprises 4
54
55 items scored on a 6-point Likert scale (range, 1–6), with a higher score indicating
56
57 worse FCR. Depression will be assessed using the Patient Health Questionnaire-9
58
59
60

1
2
3
4
5
6 42. Fatigue will be assessed by the Cancer Fatigue Scale. Sleep will be assessed by
7
8 the Athens Insomnia Scale^{43 44}. Health-related QOL will be assessed using the
9
10 EuroQol 5 Dimensions questionnaire^{45 46}.
11
12
13
14
15

16 *Biological assessments*

17
18 To assess changes in gut microbiota, intestinal metabolites, and intestinal
19 immunity⁴⁷, a 1-g fecal sample will be obtained at baseline and at 12 weeks. Blood
20
21 compositions of n-3 polyunsaturated fatty acids⁴⁸ will be assessed from capillary
22
23 dried blood spot samples (approximately 80 μ L) at baseline⁴⁹.
24
25
26
27
28
29
30

31 *Medical economic costs*

32
33 For cost-benefit analysis, the number of staff, working hours, labor costs,
34
35 equipment costs, office expenses, number of unexpected medical consultations,
36
37 direct medical costs, and costs of other medical services used will be obtained.
38
39
40
41
42
43

44 **Harms**

45
46 The intervention in this research will potentially place stress on
47
48 participants physically and in terms of their time, because it will take
49
50 approximately 1 h and 30 min. There will also be temporary exhaustion, although
51
52 individual differences will be considered in exercise implementation. There are no
53
54 financial risks associated with participation in the study.
55
56
57
58
59
60

Compensation

If participants develop unexpected health issues due to study participation during or after completion of the study, treatment will be provided appropriately in the same way as standard medical care. Medical expenses at that time will be handled within the medical insurance to which the participant is enrolled. No financial compensation, except for providing the wearable device, will be given in this study.

DATA ANALYSIS

The primary endpoint, VO_{2peak} , will be calculated as follows. Measurements will be taken at the start of the intervention (0 week) and at the conclusion of the intervention (12 weeks). The analysis set for primary analyses will consist of all randomized subjects. Our primary analysis is intention-to-treat analysis and patients without outcome data will be excluded from the analyses. After completing primary endpoint data locking, analyses centering on the primary endpoint will be performed. The objective of primary analysis in this study is to investigate whether the habit-B program group (trial treatment group) surpasses the group receiving treatment as usual (control) in VO_{2peak} , the primary endpoint. One-sided tests will be used, because, if the trial intervention group is inferior to the control group, it is not important in this trial whether that difference is statistically significant. The trial will adopt a one-sided significance level of 2.5%. A between-groups comparison will be performed using an independent two-sample

1
2
3
4
5
6 t-test to determine the significance of amount of change in VO_{2peak} (mL/kg/min)
7
8 from 0 week to 12 weeks (after intervention completion) between the trial
9
10 intervention and the control groups. Secondary endpoint analyses will be
11
12 performed with the goal of supplementing the primary analyses. The detailed
13
14 methods for supplementary analyses will be specified in the Statistical Analysis
15
16 Plan before the study data is fixed. Once all data has been locked following
17
18 conclusion of the primary analysis period and follow-up, final analyses will be
19
20 performed.
21
22
23
24
25
26
27
28

29 **Sample size estimation**

30
31 The main hypothesis of this study is that the intervention group will
32
33 significantly surpass the control group in terms of the amount of change in VO_{2peak}
34
35 from 0 week to 12 weeks. Regarding the clinical significance of the results of an
36
37 exercise program, it is common to use an increase of 10% in VO_{2peak} to evaluate the
38
39 effects of an exercise program⁵⁰. As such, an increase of 10% from VO_{2peak} at the
40
41 start of exercise has been established for this trial. According to a previous study of
42
43 intervention similar to that in the present study⁵¹, the standard deviation for the
44
45 VO_{2peak} of the intervention group was 2.6 mL/kg/min. Based on the above
46
47 hypothesis, by estimating the number of subjects required for a one-sided 2.5%
48
49 and a power of 80% in the analysis, 28 individuals per group are necessary for a
50
51 total of 56 in both groups (SAS 9.4 software; SAS Institute Inc., Cary, NC). With the
52
53 estimation that 4 participants will drop out, enrollment of 60 patients is planned.
54
55
56
57
58
59
60

Study period

The study period of this trial will be from April 2019 to March 2021; the participant entry period will be from April 2019 to March 2020. Study enrolment, intervention, and data collection are ongoing.

PATIENT AND PUBLIC INVOLVEMENT STATEMENT

This study protocol was designed with the involvement of a breast cancer survivor who participated in this study as a researcher and coauthor. She discussed issues with other survivors in instances where survivors' preferences and opinions should be considered. In the process of creating the habit-B program, we conducted a preliminary confirmation of the feasibility and safety of this program in 5 breast cancer survivors.

ETHICAL CONSIDERATIONS AND DISSEMINATION

The protocol was approved by the Institutional Review Board of the National Cancer Center Research Ethical Review Committee on 28 February 2019 (ID: 2018-274). The results obtained will be submitted for publication in a peer-reviewed international journal, and the main relevant findings will be presented at conferences.

DISCUSSION

An excellent review by Shapiro et al. affirms the positive role that high levels of physical activity play in improving not only health-related QOL and symptom management (e.g., chronic pain, fatigue, insomnia, sexual dysfunction, metabolic syndrome, bone loss, cognitive dysfunction, and depression), but also return to work in cancer survivors⁵². In addition, increased cardiorespiratory fitness may decrease all-cause mortality among cancer survivors^{53,54}. However, there are currently no effective home-based exercise programs available for improving cardiorespiratory fitness for breast cancer survivors. No studies have precisely investigated cardiorespiratory fitness⁵⁵; however, a small pilot study did estimate VO_2 based on subjective exercise intensity among Japanese breast cancer survivors. Accordingly, the present study seeks to confirm whether our originally developed home-based exercise program (habit-B program) improves VO_{2peak} compared with treatment as usual with wearable device in sedentary breast cancer survivors in Japan. With the assumption that the program will be widely implemented if successful, it was designed to be (1) home based, (2) quick to implement (only 10 min in total), (3) use only body weight exercises involving the lower limbs, and (4) utilize a wearable device for which personalized ICT support is available. We believe that no similar studies have been implemented.

If it is found that the habit-B program is effective in increasing VO_{2peak} , we will then proceed to the next trial, aiming for its widespread implementation in society. Specifically, the aims of the next study will be (1) to investigate whether

1
2
3
4
5
6 intervention using the program developed in this research but presented in a
7
8 simpler format is effective in establishing exercise habits and (2) to assess whether
9
10 the program can be implemented in societies in Eastern Asia, including in both
11
12 urban and rural Japan and other East Asian countries.
13
14

15
16 We strongly believe that a successful support team comprising specialists in
17
18 the field of exercise science, medicine, rehabilitation, nursing, and patient
19
20 advocacy, as involved in this study, will provide a new horizon in cancer
21
22 survivorship care.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We sincerely thank Dr. Hiroji Iwata, Dr. Hirokazu Arai, Ms. Noriko Watanabe, Dr. Noriaki Tatematsu, Dr. Hikaru Ihira, Mr. Tomoyasu Chigahara, Dr. Taro Ueno, Dr. Shinji Fukuda, and Dr. Eiko Saito for their generous support for the study. We also thank Ms. Ayako Sato for her role as an exercise model.

Contributors KT, EO, RO, YS, TK, and YM conceived the study and drafted the original protocol. KT, EO, RO, YS, TS, AK, TU, TK, and YM participated in refining the protocol. TU developed app and EDC system and managed datacenter. AK played a major role in the statistical analysis. KT, EO, TK, and NS contributed to developing the exercise program. KT, EO and YM drafted the manuscript. All authors participated in, read, and approved the final manuscript.

Funding This study is supported by a National Cancer Center Research and Development Fund (30-A-17).

Competing interests EO has received research support from Nippon Suisan Kaisha, Ltd. YJM has received speaker fees from Pfizer, Mochida, Eli Lilly, Morinaga Milk, and NTT Data and is conducting collaborative research with Morinaga Milk. AK has received speaking fees from Chugai Pharmaceutical Co., Ltd. All other authors declare that they have no competing interests regarding this work.

Ethics approval. The protocol was approved by the Institutional Review Board of the National Cancer Center on 28 February 2019 (ID: 2018-347).

FIGURE LEGENDS

Figure 1. Flow diagram of study participants. HIIT, high-intensity interval training; ICT, information and communication technology.

Figure 2. Study design of the habit-b program (**h**ome-based high-intensity interval training **and** **b**ehavioral modification using **i**nformation and communication **t**echnology on cardiorespiratory fitness and exercise habits for sedentary **b**reast cancer survivors). HIIT, high-intensity interval training; ICT, information and communication technology.

Figure 3. Screenshots of the application for the smartphone-based exercise movie.

Figure 4. Sample of high-intensity interval training using body weight exercise.

Figure 5. Brochure reminding participants about the importance of exercise and providing instructions about physical activity in daily life.

References

1. Denlinger CS, Sanft T, Baker KS, et al. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017;15(9):1140–63. doi: 10.6004/jnccn.2017.0146 [published Online First: 2017/09/07]
2. Public survey about cancer control in Japan. (*the Cabinet Office*), <https://survey.gov-online.go.jp/h26/h26-gantaisaku/5.html> (accessed on 2018/Aug./10)
3. Denlinger CS, Carlson RW, Are M, et al. Survivorship: Introduction and Definition: Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network : JNCCN* 2014;12(1):34–45.
4. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA: A Cancer Journal for Clinicians* 2012;62(4):242–74. doi: 10.3322/caac.21142
5. Hori M MT, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Japanese journal of clinical oncology* 2015;45(9):884–91.
6. Rock CL, Flatt SW, Byers TE, et al. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. *J Clin Oncol* 2015;33(28):3169–76. doi: 10.1200/JCO.2015.61.1095 [published Online First: 2015/08/19]
7. Kuwabara M, Kuwabara R, Niwa K, et al. Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. *Nutrients* 2018;10(8) doi: 10.3390/nu10081011 [published Online First: 2018/08/08]
8. Rogers LQ, Courneya KS, Anton PM, et al. Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled

- 1
2
3
4
5
6 trial. *Breast Cancer Res Treat* 2015;149(1):109–19. doi: 10.1007/s10549-014-
7 3216-z [published Online First: 2014/11/25]
8
- 9 9. Dolan LB, Campbell K, Gelmon K, et al. Interval versus continuous aerobic
10 exercise training in breast cancer survivors—a pilot RCT. *Support Care*
11 *Cancer* 2016;24(1):119–27. doi: 10.1007/s00520-015-2749-y [published
12 Online First: 2015/05/10]
13
- 14 10. Tanaka H, Desouza CA, Jones PP, et al. Greater rate of decline in maximal
15 aerobic capacity with age in physically active vs. sedentary healthy women.
16 *Journal of applied physiology (Bethesda, Md : 1985)* 1997;83(6):1947–53. doi:
17 10.1152/jappl.1997.83.6.1947 [published Online First: 1998/02/14]
18
- 19 11. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death
20 in women: the St James Women Take Heart Project. *Circulation*
21 2003;108(13):1554–9. doi: 10.1161/01.Cir.0000091080.57509.E9 [published
22 Online First: 2003/09/17]
23
- 24 12. Peel AB, Thomas SM, Dittus K, et al. Cardiorespiratory fitness in breast cancer
25 patients: a call for normative values. *Journal of the American Heart*
26 *Association* 2014;3(1):e000432. doi: 10.1161/jaha.113.000432 [published
27 Online First: 2014/01/15]
28
- 29 13. Tabata I, Nishimura K, Kouzaki M, et al. Effects of moderate-intensity endurance
30 and high-intensity intermittent training on anaerobic capacity and VO2max.
31 *Med Sci Sports Exerc* 1996;28(10):1327–30. [published Online First:
32 1996/10/01]
33
- 34 14. Batacan RB, Jr., Duncan MJ, Dalbo VJ, et al. Effects of high-intensity interval
35 training on cardiometabolic health: a systematic review and meta-analysis of
36 intervention studies. *British journal of sports medicine* 2017;51(6):494–503.
37 doi: 10.1136/bjsports-2015-095841 [published Online First: 2016/11/01]
38
- 39 15. Mallol M, Bentley DJ, Norton L, et al. Comparison of Reduced-Volume High-
40 Intensity Interval Training and High-Volume Training on Endurance
41 Performance in Triathletes. *International journal of sports physiology and*
42 *performance* 2019;14(2):239–45. doi: 10.1123/ijsp.2018-0359 [published
43 Online First: 2018/08/07]
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


16. Mugele H, Freitag N, Wilhelmi J, et al. High-intensity interval training in the therapy and aftercare of cancer patients: a systematic review with meta-analysis. *J Cancer Surviv* 2019 doi: 10.1007/s11764-019-00743-3 [published Online First: 2019/02/27]
17. McRae G, Payne A, Zelt JG, et al. Extremely low volume, whole-body aerobic-resistance training improves aerobic fitness and muscular endurance in females. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme* 2012;37(6):1124-31. doi: 10.1139/h2012-093 [published Online First: 2012/09/22]
18. Gresham G, Hendifar AE, Spiegel B, et al. Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. *npj Digital Medicine* 2018;1(1):27. doi: 10.1038/s41746-018-0032-6
19. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans Physical Activity Guidelines for Americans Physical Activity Guidelines for Americans. *JAMA* 2018;320(19):2020-28. doi: 10.1001/jama.2018.14854
20. Akechi T, Yamaguchi T, Uchida M, et al. Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial. *BMJ Open* 2018;8(11):e024794. doi: 10.1136/bmjopen-2018-024794 [published Online First: 2018/11/11]
21. Gresham G, Schrack J, Gresham LM, et al. Wearable activity monitors in oncology trials: Current use of an emerging technology. *Contemp Clin Trials* 2018;64:13-21. doi: 10.1016/j.cct.2017.11.002 [published Online First: 2017/11/14]
22. Ministry of Health, Labour and Welfare Summary of results of the national nutrition survey, Japan. 2017.;<https://www.mhlw.go.jp/toukei/itiran/gaiyo/k-eisei.html> (accessed on 2018/Aug./10 (in Japanese))
23. Bandura A. Health promotion by social cognitive means. *Health education & behavior : the official publication of the Society for Public Health Education*

- 2004;31(2):143–64. doi: 10.1177/1090198104263660 [published Online First: 2004/04/20]
24. Stacey FG, James EL, Chapman K, et al. A systematic review and meta-analysis of social cognitive theory-based physical activity and/or nutrition behavior change interventions for cancer survivors. *J Cancer Surviv* 2015;9(2):305–38. doi: 10.1007/s11764-014-0413-z [published Online First: 2014/11/30]
25. Abedtash H, Holden RJ. Systematic review of the effectiveness of health-related behavioral interventions using portable activity sensing devices (PASDs). *Journal of the American Medical Informatics Association : JAMIA* 2017;24(5):1002–13. doi: 10.1093/jamia/ocx006 [published Online First: 2017/03/25]
26. Taylor HL, Buskirk E, Henschel A. Maximal oxygen intake as an objective measure of cardio-respiratory performance. *Journal of applied physiology* 1955;8(1):73–80. doi: 10.1152/jappl.1955.8.1.73 [published Online First: 1955/07/01]
27. Whipp BJ, Davis JA, Torres F, et al. A test to determine parameters of aerobic function during exercise. *Journal of applied physiology: respiratory, environmental and exercise physiology* 1981;50(1):217–21. doi: 10.1152/jappl.1981.50.1.217 [published Online First: 1981/01/01]
28. Ross RM, Murthy JN, Wollak ID, et al. The six minute walk test accurately estimates mean peak oxygen uptake. *BMC pulmonary medicine* 2010;10:31. doi: 10.1186/1471-2466-10-31 [published Online First: 2010/05/28]
29. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc* 2014;15(2):95–101. doi: 10.1016/j.jamda.2013.11.025 [published Online First: 2014/01/28]
30. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. *The New England journal of medicine* 2009;361(7):664–73. doi: 10.1056/NEJMoa0810118 [published Online First: 2009/08/14]
31. Neil-Sztramko SE, Kirkham AA, Hung SH, et al. Aerobic capacity and upper limb strength are reduced in women diagnosed with breast cancer: a systematic

- 1
2
3
4
5
6 review. *Journal of physiotherapy* 2014;60(4):189–200. doi:
7 10.1016/j.jphys.2014.09.005 [published Online First: 2014/12/03]
8
- 9 32. Van der Weijden–Van Doornik EM, Slot DE, Burtin C, et al. Grip Strength in
10 Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine
11 Therapy: Systematic Review. *Phys Ther* 2017;97(9):904–14. doi:
12 10.1093/ptj/pzx069 [published Online First: 2017/10/04]
13
- 14 33. Herrero F, San Juan AF, Fleck SJ, et al. Combined aerobic and resistance
15 training in breast cancer survivors: A randomized, controlled pilot trial.
16 *International journal of sports medicine* 2006;27(7):573–80. doi: 10.1055/s-
17 2005–865848 [published Online First: 2006/06/28]
18
- 19 34. Foley MP, Hasson SM. Effects of a Community–Based Multimodal Exercise
20 Program on Health–Related Physical Fitness and Physical Function in Breast
21 Cancer Survivors:A Pilot Study. *Integrative Cancer Therapies*
22 2016;15(4):446–54. doi: 10.1177/1534735416639716
23
- 24 35. Maruya K, Fujita H, Arai T, et al. Identifying elderly people at risk for cognitive
25 decline by using the 2–step test. *J Phys Ther Sci* 2018;30(1):145–49. doi:
26 10.1589/jpts.30.145
27
- 28 36. Organization WH. Global Physical Activity Surveillance [Available from:
29 <http://www.who.int/ncds/surveillance/steps/GPAQ/en/> accessed Aug. 10
30 2018.
31
- 32 37. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity
33 questionnaire (GPAQ) in assessing levels and change in moderate–vigorous
34 physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255.
35 doi: 10.1186/1471–2458–14–1255 [published Online First: 2014/12/11]
36
- 37 38. Chu AH, Ng SH, Koh D, et al. Reliability and Validity of the Self– and Interviewer–
38 Administered Versions of the Global Physical Activity Questionnaire (GPAQ).
39 *PLoS One* 2015;10(9):e0136944. doi: 10.1371/journal.pone.0136944 [published
40 Online First: 2015/09/04]
41
- 42 39. Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ):
43 nine country reliability and validity study. *Journal of physical activity & health*
44 2009;6(6):790–804. [published Online First: 2010/01/28]
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


- 1
2
3
4
5
6 40. Vickberg SM. The Concerns About Recurrence Scale (CARS): a systematic
7 measure of women's fears about the possibility of breast cancer recurrence.
8 *Ann Behav Med* 2003;25(1):16–24.
9
- 10 41. Momino K, Akechi T, Yamashita T, et al. Psychometric Properties of the
11 Japanese Version of the Concerns About Recurrence Scale (CARS–J).
12 *Japanese Journal of Clinical Oncology* 2014;44(5):456–62. doi:
13 10.1093/jjco/hyu032
14
- 15 42. Muramatsu K, Miyaoka H, Kamijima K, et al. The patient health questionnaire,
16 Japanese version: validity according to the mini–international
17 neuropsychiatric interview–plus. *Psychological reports* 2007;101(3 Pt 1):952–
18 60. doi: 10.2466/pr0.101.3.952–960 [published Online First: 2008/02/01]
19
- 20 43. Okajima I, Nakajima S, Kobayashi M, et al. Development and validation of the
21 Japanese version of the Athens Insomnia Scale. *Psychiatry and clinical
22 neurosciences* 2013;67(6):420–25. doi: 10.1111/pcn.12073 [published Online
23 First: 2013/08/05]
24
- 25 44. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation
26 of an instrument based on ICD–10 criteria. *Journal of psychosomatic
27 research* 2000;48(6):555–60.
28
- 29 45. Rabin R, de Charro F. EQ–5D: a measure of health status from the EuroQol
30 Group. *Annals of medicine* 2001;33(5):337–43. [published Online First:
31 2001/08/09]
32
- 33 46. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ–5D population value set:
34 the case of Japan. *Health economics* 2002;11(4):341–53. doi: 10.1002/hec.673
35 [published Online First: 2002/05/15]
36
- 37 47. Monda V, Villano I, Messina A, et al. Exercise Modifies the Gut Microbiota with
38 Positive Health Effects. *Oxidative medicine and cellular longevity*
39 2017;2017:3831972. doi: 10.1155/2017/3831972 [published Online First:
40 2017/03/31]
41
- 42 48. Zebrowska A, Mizia–Stec K, Mizia M, et al. Omega–3 fatty acids supplementation
43 improves endothelial function and maximal oxygen uptake in endurance–
44 trained athletes. *European journal of sport science* 2015;15(4):305–14. doi:
45 10.1080/17461391.2014.949310 [published Online First: 2014/09/02]
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 49. Liu G, Muhlhausler BS, Gibson RA. A method for long term stabilisation of long
7 chain polyunsaturated fatty acids in dried blood spots and its clinical
8 application. *Prostaglandins, leukotrienes, and essential fatty acids*
9 2014;91(6):251–60. doi: 10.1016/j.plefa.2014.09.009 [published Online First:
10 2014/12/03]
11
12
13
14 50. Scribbans TD, Vecsey S, Hankinson PB, et al. The Effect of Training Intensity on
15 VO2max in Young Healthy Adults: A Meta-Regression and Meta-Analysis.
16 *International journal of exercise science* 2016;9(2):230–47. [published Online
17 First: 2016/05/18]
18
19
20
21 51. Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise
22 training in postmenopausal breast cancer survivors: cardiopulmonary and
23 quality of life outcomes. *J Clin Oncol* 2003;21(9):1660–8. doi:
24 10.1200/jco.2003.04.093 [published Online First: 2003/05/02]
25
26
27 52. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. *The*
28 *New England journal of medicine* 2001;344(26):1997–2008. doi:
29 10.1056/nejm200106283442607 [published Online First: 2001/06/30]
30
31
32 53. Peel JB, Sui X, Adams SA, et al. A prospective study of cardiorespiratory fitness
33 and breast cancer mortality. *Med Sci Sports Exerc* 2009;41(4):742–8. doi:
34 10.1249/MSS.0b013e31818edac7 [published Online First: 2009/03/12]
35
36
37 54. Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-
38 related decline across the breast cancer survivorship continuum. *J Clin*
39 *Oncol* 2012;30(20):2530–7. doi: 10.1200/JCO.2011.39.9014 [published Online
40 First: 2012/05/23]
41
42
43
44 55. Okumatsu K, Tsujimoto T, Wakaba K, et al. Physical fitness level in Japanese
45 breast cancer survivors. *Japanese Journal of Physical Fitness and Sports*
46 *Medicine* 2018;67(2):169–76. doi: 10.7600/jspfsm.67.169
47
48
49
50
51
52
53
54
55
56
57
58
59
60



189x195mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



3 min and 10 sec Warm up	Squat	rest	Lunge	rest	Squat	rest	Lunge	rest	Squat	rest	Lunge	rest	Squat	rest	Lunge	3 min cool down
	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	10 s	20 s	

10 min

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



NCC 法政大学
habit-B

1人ではなくみんなで頑張りましょう!

【TSUKIJI habit-B プロジェクト】
現在、私たちは乳がんサバイバー向けに有酸素能力を向上させるための運動プログラムを開発しています。

〒104-0045 東京都中央区豊町5-1-1
https://www.ncc.go.jp/cj/cjpb/ds/online/habit_support/project/20181228175920.html
お問い合わせ habit-Bプロジェクト
国立がん研究センター 健康増進部/法政大学 健康増進部



Let's training

乳がんサバイバーのあなたへ

体力向上のためのトレーニング

自宅で継続・安心トレーニングのご紹介



こんなことありませんか？

<input type="checkbox"/> 体力の低下を感じている	<input type="checkbox"/> 旧もとの体力に戻したい
<input type="checkbox"/> 疲れやすくなる	<input type="checkbox"/> 一人でトレーニングは不安だ
<input type="checkbox"/> そろそろ運動をはじめたい	<input type="checkbox"/> 毎日を楽しみたい

毎日の生活に運動を取り入れましょう!

疲れにくいカラダをつくる4つの運動

心臓機能を高く維持することは疲れにくいカラダをつくり、乳がんサバイバーにとってきわめて重要です。下記の運動は、ふとももやおしりの筋肉を意識しながら丁寧に実施することで運動中に心拍数を上昇させて心臓機能を向上させます。さらにこれらの運動は認識やサルコペニアの予防にも役立ちます。

Step 1



Point
膝つま先の向きを揃えましょう

Step 2



Point
膝つま先の向きを揃えて、両足のつま先を揃えましょう

Step 3



Point
膝を深く落としましょう

Step 4



Point
しゃがみ込むとき、膝立ての姿勢から立ち上がり、膝を一歩スライドの姿勢を繰り返しましょう。

運動強度 ★	運動強度 ★★	運動強度 ★★★	運動強度 ★★★★★
<p>スクワット</p> <p>足を肩幅からやや広めに広げ、お尻を後ろに突き出しながら、上体を倒し過ぎないように膝の曲げ伸ばしを行います。</p>	<p>フロントランジ</p> <p>片足づつ足を前に出しましょう。背筋を伸ばして、前に出した足の膝がつま先より前に出ないように膝を曲げましょう。</p>	<p>ステイパーズランジ</p> <p>左右のジャンプ動作が含まれます。膝へ負担がかかる姿勢を避けるように注意しましょう。背筋の曲も、膝つま先の向きを揃えて、次の動作へスムーズにつなげられるようにしましょう。</p>	<p>バーピー</p> <p>全身を効率よく動かす運動です。</p> <ol style="list-style-type: none"> ①しゃがみこんで手をつく ②手をついたまま飛び跳ねて足を後ろに伸ばして、膝が足の姿勢になる ③飛び跳ねて膝を曲げて、しゃがみこんだ姿勢にもどる ④立ち上がる



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym (p1)
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry (p4, 20)
	2b	All items from the World Health Organization Trial Registration Data Set (n/a)
Protocol version	3	Date and version identifier (p4, 20)
Funding	4	Sources and types of financial, material, and other support (p23)
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors (p23)
	5b	Name and contact information for the trial sponsor (p23)
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities (n/a)
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) (n/a)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention (p6)
	6b	Explanation for choice of comparators (p11)
Objectives	7	Specific objectives or hypotheses (p6)
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) (p8)

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained(p5)
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) (p8,9)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered(p9-11)
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) (p13)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) (p11)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial(p12,13)
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended(p14-18)
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure 1,2, and Table 1)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations(p19)
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size(n/a)

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions(p8,12)
---------------------	-----	---

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned(p8,12)
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions(p8,12)
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how(p12)
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial(n/a)
17			
18			
19			

Methods: Data collection, management, and analysis

21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
22	methods		trial data, including any related processes to promote data quality (eg,
23			duplicate measurements, training of assessors) and a description of
24			study instruments (eg, questionnaires, laboratory tests) along with
25			their reliability and validity, if known. Reference to where data
26			collection forms can be found, if not in the protocol(p18)
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols(p10,13)
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol(p11,12)
36			
37			
38			
39			
40	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
41	methods		Reference to where other details of the statistical analysis plan can be
42			found, if not in the protocol(p18,19)
43			
44		20b	Methods for any additional analyses (eg, subgroup and adjusted
45			analyses) (p18,19)
46			
47		20c	Definition of analysis population relating to protocol non-adherence
48			(eg, as randomised analysis), and any statistical methods to handle
49			missing data (eg, multiple imputation) (p18,19)
50			
51			

Methods: Monitoring

52			
53			
54	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
55			and reporting structure; statement of whether it is independent from
56			the sponsor and competing interests; and reference to where further
57			details about its charter can be found, if not in the protocol.
58			Alternatively, an explanation of why a DMC is not needed(p11,12)
59			
60			

1		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial(n/a)
2			
3			
4			
5			
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct(p17)
7			
8			
9			
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor(p11,12)
11			
12			
13			
14			

Ethics and dissemination

15			
16			
17	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval(p4)
18			
19			
20			
21	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) (n/a)
22			
23			
24			
25			
26	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) (n/a)
27			
28			
29		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable(n/a)
30			
31			
32	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial(p12)
33			
34			
35			
36			
37	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site(p23)
38			
39			
40	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators(n/a)
41			
42			
43			
44			
45	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation(p17,18)
46			
47			
48	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions(p4,20)
49			
50			
51			
52			
53			
54			
55		31b	Authorship eligibility guidelines and any intended use of professional writers(p11)
56			
57			
58		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code(n/a)
59			
60			

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates(n/a)
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable(p17)

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only